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ABSTRACT
The Democratization and Development of Cell-free Protein Synthesis
Max Zachary Levine
Cell-free protein synthesis (CFPS) using crude lysates has developed into a robust
platform technology over the last 60 years to express numerous types of recombinant proteins.
The open-nature, elimination of reliance on cell viability, and focus of all energy towards
production of the protein of interest represent substantial advantages of CFPS over in vivo protein
expression methods. CFPS has provided new opportunities across a series of research fields that
include metabolic engineering, therapeutic and vaccine development, education, biosensors, and
many more. In recent years, optimizations of CFPS have even allowed the platform to reach the
industrial level of protein production. Although there have been many advancements toward
CFPS development, the democratization of the platform to a wide variety of educational,
research, and industrial institutions has lacked due to an absence of resources for new users as
well as a limited number of developments toward redesigning the tedious and time-consuming
protocols to generate robust cell extract. To address these challenges to CFPS implementation, a
comprehensive review spanning numerous cell lines with their respective applications,
methodologies, and reaction formats were provided in addition to detailed protocols outlining the
process of going from E. coli cells to a completed CFPS reaction. Together, these resources
provide the scientific community with easily accessible resources for CFPS implementation.
Moreover, the aforementioned protocols were redesigned from a four-day process into one that
may be completed in under 24-hour’s time with very little researcher oversight. The resulting
workflow maintained the robustness of prior methods but generated 400% more extract
compared to traditional methods via a set-it-and-forget-it approach. To date, the works presented
herein have garnered tremendous viewership from the CFPS research community with a
substantial following among all three of the articles. Moving forward, I anticipate that these works
will continue to bring new users into the CFPS field through the ease of access to these
resources and through the advance of the simplistic and reproducible new workflow for
preparation of robust E. coli cell extract.
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Chapter 1

1. INTRODUCTION
1.1 A USER’S GUIDE TO CELL-FREE PROTEIN SYNTHESIS
Modified from a review submitted to Methods and Protocols
Nicole E. Gregorio

1,2

, Max Z. Levine

1,3

, and Javin P. Oza

1,2,

*

1.1.1 Introduction
Cell-free protein synthesis (CFPS) emerged about 60 years ago as a platform used
by Nirenberg and Matthaei to decipher the genetic code and discover the link between
mRNA and protein synthesis [1]. Since this discovery, the CFPS platform has grown to
enable a variety of applications, from functional genomics to large-scale antibody
production [2,3]. Currently, CFPS has been implemented using cell extracts from
numerous different organisms, with their unique biochemistries enabling a broad set of
applications. In an effort to assist the user in selecting the CFPS platform that is best
suited to their experimental goals, this review provides an in-depth analysis of high
adoption CFPS platforms in the scientific community, the applications that they enable,
and methods to implement them. We also review applications enabled by low adoption
platforms, including applications proposed in emerging platforms. We hope that this will
simplify new users’ choice between platforms, thereby reducing the barrier to
implementation and improving broader accessibility of the CFPS platform.
The growing interest in CFPS is the result of the key advantages associated with the
open nature of the platform. The CFPS reaction lacks a cellular membrane and a
functional genome, and consequently is not constrained by the cell’s life objectives [4].
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Therefore, the metabolic and cytotoxic burdens placed on the cell when attempting to
produce large quantities of recombinant proteins in vivo are obviated in CFPS [5]. The
CFPS platform is amenable to direct manipulation of the environment of protein production
because it is an open system (Figure 1). In some cases higher protein titers can be
achieved using CFPS because all energy in the system is channeled toward producing
the protein of interest (Figure 2) [6]. Moreover, CFPS reactions are flexible in their setup,
allowing users to utilize a variety of reaction formats, such as batch, continuous flow, and
continuous exchange, in order to achieve the desired protein titer (Figure 3). These
advantages make CFPS optimally suited for applications such as the production of
difficult-to-synthesize proteins, large proteins, proteins encoded by high GC content
genes, membrane proteins, and virus-like particles (Figure 4A & 5A). The scalable nature
of CFPS allows it to support the discovery phase through high-throughput screening as
well as the production phase through large-scale biomanufacturing. Additional high impact
applications include education, metabolic engineering, and genetic code expansion.

2

Figure 1. A comparison of cell-free and in vivo protein synthesis methods.
Through visualization of the main steps of in vitro and in vivo protein expression,
the advantages of cell-free protein synthesis emerge. These include the
elimination of the transformation step, an open reaction for direct manipulation of
the environment of protein production, the lack of constraints based on the cell’s
life objectives, the channeling of all energy toward production of the protein of
interest, and the ability to store extracts for on-demand protein expression. Green
cylinders represent synthesized green fluorescent protein (GFP).
While the number of cell-free platforms based on different organisms has grown
substantially since its conception, the basic steps for successful implementation of a cellfree platform are analogous across platforms (Figure 6). In brief, users must culture the
cell line of interest from which transcription and translation machinery are to be extracted.
3

Next, the user must lyse the cells while maintaining ribosomal activity in the lysate, prepare
cell extract by clarifying the lysate through various methods, and then utilize the prepared
cell extract in CFPS reactions to synthesize the protein of interest. These basic steps have
many nuanced variations from platform to platform, and even within platforms. Lysis
methods in particular are extremely variable and commonly used methods include
homogenization, sonication, French press, freeze thaw, nitrogen cavitation, bead beating
[7]. Extract preparation varies by centrifugation speeds, run off reactions, dialysis, or
treatment with nucleases to remove endogenous DNA or RNA. Here, we report
methodologies used most commonly for obtaining highest volumetric yields of the target
protein (Tables 1–3). We also report low adoption platforms including emerging platforms
that adapt these methods for continued innovations in CFPS.
Based on nearly 60 years of literature, we have divided CFPS platforms into two
categories: high adoption and low adoption platforms. The latter also includes emerging
platforms. High adoption platforms for CFPS are based on extracts from the following cell
lines: Escherichia coli, Spodoptera frugiperda (insect), Saccharomyces cerevisiae (yeast),
Chinese hamster ovary, rabbit reticulocyte lysate, wheat germ, and HeLa cells. These
platforms have been well optimized and utilized since their conception and are most easily
implemented by new users due to the breadth of supporting literature (Figure 4). Platforms
that have experienced low adoption to date include Neurospora crassa, Streptomyces,
Vibrio natriegens, Bacillus subtilis, Tobacco, Arabidopsis, Pseudomonas Putida, Bacillus
megaterium, Archaea, and Leishmania tarentolae. These platforms have not been widely
used or developed, and some have even emerged in the last two years as promising
candidates for new applications (Figure 5). Trends in CFPS literature demonstrate that
there is continued development and optimization of platforms, and the emerging platforms
are likely to be the source of rapid innovations. We also anticipate significant development
toward the broad dissemination and utilization of CFPS platforms.
4

1.1.2. CFPS Reaction Formats
As an open and highly personalized platform, CFPS reactions can be executed in a
variety of formats, including coupled, uncoupled, batch, continuous flow, continuous
exchange, lyophilized, or microfluidic formats depending on the needs of the user.
Additionally, there are a variety of commercial CFPS kits available for users looking to
implement CFPS quickly, without the need for long-term or large-scale usage. Here we
describe the differences and utility of each format.

Figure 2. Comparison of protein yields across cell-free platforms. The volumetric
yield of each platform is reported for batch reactions producing GFP. Platforms
that report volumetric yield for reporter proteins luciferase (*) or ChiA4 (**) are
indicated. Information for batch mode protein yields of the Arabidopsis and
Neurospora crassa platforms was not found. Yields were obtained from the
following sources: E. coli [8], wheat germ [9], Vibrio natriegens [10], Leishmania
tarentolae [11], tobacco [12], HeLa [13], Pseudomonas putida [14], Streptomyces
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[15], Bacillus megaterium [16], Chinese hamster ovary [17], insect [18], Bacillus
subtilis [16], yeast [19], archaeal [20], and rabbit reticulocyte [21].
1.1.2.1. Commercial Systems
Many of the high adoption CFPS platforms have been commercialized as kits
available for users to quickly leverage the advantages of CFPS for their research. This
has generally been the best option for labs lacking the access and technical expertise
necessary to produce their own cell extracts. Commercial kits enable users to implement
CFPS easily, but for extensive usage, they may not be cost-effective. For example, in
house prepared E. coli CFPS costs about $0.019/L of reaction while commercial lysatebased kits cost $0.15–0.57/L of reaction [22]. Currently commercial kits exist for E. coli
(New England Biolabs, Promega, Bioneer, Qiagen, Arbor Biosciences, ThermoFisher,
Creative Biolabs), rabbit reticulocyte (Promega, Creative Biolabs), wheat germ (Promega,
Creative Biolabs), Leishmania tarentolae (Jena Bioscience), insect (Qiagen, Creative
Biolabs), Chinese hamster ovary (Creative Biolabs), HeLa (ThermoFisher, Creative
Biolabs), and plant cells (LenioBio).
In addition to cell-extract-based CFPS kits, the PURExpress kit is comprised of a
reconstitution of purified components of the transcription and translation machinery from
E. coli. Specifically, the PURE (protein synthesis using recombinant elements) system
utilizes individually purified components in place of cell extract. These include 10
translation factors: T7 RNA polymerase, 20 aminoacyl-tRNA synthetases, ribosomes,
pyrophosphatase, creatine kinase, myokinase, and nucleoside diphosphate kinase
[23,24]. This system requires overexpression and purification of each component but
benefits from the absence of proteases and nucleases, and the defined nature of the
system. Overall, the PURE system allows for high purity and somewhat easier
manipulation of the reaction conditions than even cell-extract-based CFPS [23]. Moreover,
6

if all synthesized components are affinity-tagged, they can be easily removed posttranslationally to leave behind the protein of interest [24]. This system may provide
advantages for the synthesis of properly folded proteins with supplemented chaperones,
genetic code expansion, and display technologies [23–25]. The PURE system would be
significantly more time-consuming to produce in-house but is available commercially (New
England BioLabs, Creative Biolabs, Wako Pure Chemical Industries). However, these kits
are expensive ($0.99/L of reaction) when compared to both in-house and commercially
available extract-based CFPS [22]. They are also significantly less productive (~100
µg/mL) than their extract-based E. coli CFPS counterpart (Figure 2) [23,26].
1.1.2.2. Coupled and Uncoupled Formats
CFPS reactions can be performed in coupled or uncoupled formats, and the choice is
dependent on the platform being used and the user’s needs. Coupled reactions allow
transcription and translation to take place within a single tube, such that the supplied DNA
template can be transcribed into mRNA, which is then translated into protein within a onepot reaction. The advantage of coupled CFPS is the ease of reaction setup, but it may
result in suboptimal yields for eukaryotic platforms. Uncoupled reactions typically consist
of an in vitro transcription reaction followed by mRNA purification; the purified transcripts
are then supplied to the cell-free translation reaction containing the cell extract for
production of the protein of interest. Uncoupled reactions are more often utilized in
eukaryotic CFPS platforms due to mRNA processing for more efficient translation of
certain transcripts. As an example, pseudouridine modification for mRNA in the rabbit
reticulocyte platform has been demonstrated to enhance translation [27]. Uncoupled
reactions also allow for different conditions between transcription and translation
reactions, which can improve yields [9]. Uncoupled reactions can be achieved in any
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platform by supplying the reaction with mRNA instead of DNA, but mRNA can be more
difficult to handle and does degrade more quickly in the CPFS reaction [28].
1.1.2.3. Batch, Continuous Flow, and Continuous Exchange Formats
CFPS reactions can be performed in batch format for simplified setup, or in continuous
formats for improved protein yields. Reactions are most easily, quickly, and cheaply set
up in batch format because all necessary reactants are added to a single tube and
incubated for protein synthesis to occur (Figure 3). However, the duration of a batch
reaction is dependent on the amount of substrate available and the amount of inhibitory
byproduct produced, which can result in low yields for some platforms (Figure 2). On the
other hand, continuous flow and continuous exchange CFPS reactions utilize a twochamber system to supply reactants and remove products, for increased reaction duration
and higher protein yields [29–32]. In continuous exchange cell-free (CECF), the CFPS
reaction is separated from a reactant-rich feed solution via a semi-permeable membrane,
such that new reactants move into the reaction and byproducts move out, while the protein
product remains in the reaction compartment (Figure 3) [31]. For continuous flow cell-free
(CFCF), the feed solution is continuously pumped into the reaction chamber, while the
protein of interest and other byproducts are pushed out through an ultrafiltration
membrane (Figure 3) [33].
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Figure 3. Comparison of batch, continuous flow, and continuous exchange
reaction formats. Batch reactions contain all the necessary reactants within a
single reaction vessel. Continuous exchange formats utilize a dialysis membrane
that allows reactants to move into the reaction and byproducts to move out, while
the protein of interest remains in the reaction compartment. Continuous flow
formats allow a feed solution to be continuously pumped into the reaction
chamber while the protein of interest and other reaction byproducts are filtered
out of the reaction.
Batch reactions are well suited to platforms that exhibit high protein yields and to
applications that require simple and fast setup (Figure 2). These applications may include
high-throughput screening and education. Moreover, batch reactions can be easily scaled
up in platforms such as E. coli and wheat germ, due to the ability to scale growth and
reaction setup linearly. Platforms such as Chinese hamster ovary, yeast, and rabbit
reticulocyte, which suffer from low protein yields, may require a CFCF or CECF setup to
generate sufficient amounts of protein. Continuous formats have already been
successfully constructed in Chinese hamster ovary, insect, E. coli, wheat germ, and yeast
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[30,32,34–37]. For example, continuous formats have allowed for the synthesis of 285
g/mL of human EGFR to be produced by the insect platform, 980 g/mL of membrane
protein in the Chinese hamster ovary platform, and up to 20,000 g/mL of protein in wheat
germ [9,38,39]. Continuous formats may also be used for large-scale protein synthesis
reactions in industrial applications [38,39]. Scale-up of CFPS reactions will be discussed
in more detail in Section 3.2.5 titled “Large-Scale.”
1.1.2.4. Lyophilization
Lyophilization, or freeze-drying, has been used as a technique to stabilize cell extracts
for long-term and higher temperature storage, and to provide a condensed format to
reduce necessary storage space. By overcoming the cold chain, lyophilization could help
enable applications such as on-demand biosensors for diagnostics, therapeutic
production in remote locations, personalized medicines, and more [40]. Lyophilization has
only been heavily pursued for E. coli extract thus far, with some additional work done on
the lyophilization of other CFPS reagents and the addition of lyoprotectant additives, and
with preliminary work done in wheat germ [41].
Traditionally, aqueous cell-extract is stored at −80 C, and its activity is reduced by
50% after just one week of storage at room temperature, with all activity lost after a month
[42]. In comparison, lyophilized extract maintains approximately 20% activity through 90
days of storage at room temperature. Importantly, the process of lyophilization does not
negatively impact reaction yields. A CFPS reaction run directly after lyophilization could
achieve the same yields as an aqueous reaction [42]. Lyophilized extract also reduces
storage volume to half and mass to about one-tenth [42]. Importantly, the process of
lyophilization itself does not negatively impact extract productivity [43]. Lyophilization of
extract has also been done on paper, rather than in a tube, to further improve storage and
distribution of cell-free technology [44,45].
10

Some work has been done to test the viability of lyophilizing CFPS reagents
necessary for a phosphoenolpyruvate-based reaction setup. These reagents were
lyophilized with or without the extract, and while viability was improved over aqueous
storage of the reagents at higher temperatures, the combined extract and reagent mixture
posed new challenges to the handling of the lyophilized powder due to the resulting texture
[42]. Other users have lyophilized the template of interest separately from otherwise fully
prepared CFPS reaction for classroom applications, such that the template is simply
rehydrated and added to the reaction pellet to begin protein synthesis [46,47]. Additionally,
lyoprotectants for cell-free applications have been briefly screened, including sucrose,
which provided no obvious benefits to storage stability [42].
1.1.2.5. Microfluidics Format
The growing field of microfluidics consists of many broad methodologies that
generally involve the manipulation of fluids on the micron scale on devices with critical
dimensions smaller than one millimeter [48]. These devices, when paired with cell-free
extracts, provide cost-effective and rapid technologies capable of high-throughput assays
to generate protein in an automated series of channels that often consist of mixers,
reactors, detectors, valves, and pumps on a miniaturized scale [49]. The utilization of
microfluidics to pioneer biomedical and diagnostic approaches for sensing and monitoring
environmental and health issues has been achieved within E. coli, wheat germ, and insect
platforms [49]. Examples of applications that utilize the microfluidics format include both
the E. coli and wheat germ platforms to test for the presence of ricin in orange juice and
diet soda through the generation of a reporter protein [50,51]. The insect platform was
also used in a Transcription-RNA Immobilization and Transfer-Translation (TRITT) system
for the production of a cytotoxic protein with simultaneous non-standard amino acid
incorporation for fluorescence labeling [52].
11

1.1.3. Applications of Cell-Free Protein Synthesis
1.1.3.1. Introduction to Platform Categorization
In the 60 years since cell-free protein synthesis emerged, a multitude of platforms
have been developed based on cell extracts from a variety of organisms. These include
extracts from bacterial, archaeal, plant, mammalian, and human cell lines. Each resulting
platform varies in ease of preparation, protein yields, and in possible applications resulting
from the unique biochemistry of the given organism. In this review, we have divided these
various platforms into two categories: high adoption and low adoption (Figures 4 and 5).
The platforms have been categorized based on our understanding of their development
and the degree to which they have been adopted by the field, as quantified by the number
of peer-reviewed publications that utilize each platform (Figures 4B and 5B). This
categorization allows new users to identify platforms that have been best established and
to explore the applications that they enable. We believe that the depth of literature
available for these platforms makes them optimally suited for newer users. Low adoption
platforms may be particularly useful for niche applications, but have not been optimized
thoroughly, or are currently emerging in the field. Therefore, these platforms may be more
difficult to implement due to minimal development. Platforms with fewer than 25 peerreviewed publications to date have been categorized as “low adoption.”
1.1.3.2. High Adoption Platforms
High adoption platforms include those based on E. coli, insect, yeast, Chinese
hamster ovary, rabbit reticulocyte lysate, wheat germ, and HeLa cells (Figure 4). These
platforms have been utilized for a variety of applications and have withstood the test of
time to establish their utility and versatility within the CFPS field. Briefly, bacterial CFPS
platforms including E. coli tend to have higher protein yields and are typically easier and
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faster to prepare (Figure 2). However, they can be limited in some applications such as
post-translational modifications, membrane protein synthesis, and other difficult-tosynthesize proteins. In such cases, eukaryotic platforms are well suited for the synthesis
of traditionally difficult proteins without requiring significant augmentation or modifications
to the cell extracts. Within the eukaryotic platforms, wheat germ provides the highest
productivity; rabbit reticulocyte, Chinese hamster ovary, HeLa, yeast, and insect platforms
give significantly lower yields but may have other advantages for post-translation
modifications, membrane proteins, or virus-like particles. In order to enable users to select
a platform that will support their experimental goals, the discussion of high adoption
platforms is application-driven. For each application, the relevant platform and reaction
formats are discussed.

Figure 4. High adoption cell-free platforms and their applications. (A) Web of the
applications enabled by high adoption cell-free platforms. The connections shown
are based on applications that have been published for each respective platform.
Applications under “difficult to synthesize proteins” include the production of
antibodies, large proteins, ice structuring proteins, and metalloproteins.
Miscellaneous applications include studies of translational machinery, genetic
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circuits, metabolic engineering, and genetic code expansion. (B) Cumulative
number of peer-reviewed publications over the last 60 years for high adoption
platforms. The metric of cumulative publications by platform is used to indicate
which platforms are most utilized, with platforms having over 25 papers
categorized as high adoption. These data were generated by totaling papers from
a PubMed Boolean search of the following: (“cell free protein synthesis” OR “in
vitro transcription translation” OR “in vitro protein synthesis” OR “cell free protein
expression” OR “tx tl” OR “cell-free translation”) AND “platform name.” The
platform name used for each search corresponds to the name listed in the graph’s
key. This information was collected on 23 December 2018, and the search results
for each platform can be found in Supplemental Information. While this metric is
an indicator of the level of adoption for each platform, it does suffer from false
positive search results, such as papers reporting studies in which the researchers
produce recombinant proteins from the organism of interest rather than from cell
extract derived from that organism.
1.1.3.2.1. Education
The open nature of the CFPS system and the resulting access to directly manipulate
cellular machinery enables inquiry-based learning opportunities that make CFPS
particularly suitable for the classroom. The first application of CFPS technology for
education is the BioBits kits, which were tested with students of various ages [46,53].
These kits offer versatile experimental options and are relatively inexpensive (about $100
for a class set). The BioBits Bright and Explorer kits represent the diversity of classroom
experiments and applications that can be enabled by CFPS, from production of fluorescent
proteins, to hydrogel production, and to identification of fruit DNA [46,53]. These
possibilities show that CFPS enables inquiry-based learning of concepts in biochemistry
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in a hands-on fashion. The stability of CFPS classroom kits is achieved through
lyophilization of reaction components. More information on lyophilization of CFPS can be
found in Section 2.4, titled “Lyophilization.”
1.1.3.2.2. Post-Translational Modifications (PTMs)
Post-translational modifications (PTMs) can greatly affect protein folding, activity, and
stability, which may be essential for therapeutic proteins, membrane proteins, and viruslike particles, among others [54]. As such, the ability to incorporate various posttranslational modifications (PTMs) into the protein of interest is a key consideration when
choosing a CFPS platform. PTMs achieved through genetic code expansion will be
discussed in Section 3.2.8.4 “Genetic Code Expansion.” Here, we cover some key PTMs
possible in each high adoption platform and the necessary modifications of the platform
that may be needed to achieve them. A key consideration is that platforms with
endogenous microsomes demonstrate a greater capacity to support PTMs. This makes
platforms such as Chinese hamster ovary, HeLa, and insect well-suited for this application,
as endogenous microsomes are formed from endoplasmic reticulum and maintained
during extract preparation. However, when endogenous microsomes are utilized, a new
“black box” is introduced to the system, which limits user control and restricts PTM choice
to those innately possible in the cell line [54].
In the rabbit reticulocyte platform, a variety of PTMs have been investigated, including
glycosylation, cleavage of signal proteins, prenylation, and disulfide bond formation [55–
61]. However, rabbit reticulocyte extract requires the addition of exogenous microsomes
for PTM incorporation. The platform has also been used to probe the specificity of signal
sequence differences between glycosylphosphatidylinositol anchoring and translocation
to the ER lumen, which was found to be sensitive to even single residue changes [56].
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Insect cell CFPS, which contains endogenous microsomes, allows for signal peptide
cleavage, glycosylation, phosphorylation, N-myristoylation, N-acetylation, prenylation, and
ubiquitination [62–70]. These possible PTMs are similar to those of rabbit reticulocyte and
other mammalian platforms [62]. Disulfide bond formation can also be achieved in these
platforms by preparing the cell extract under non-reducing conditions, and adding
glutathione along with protein disulfide isomerase to the reactions [71]. The insect cellfree platform was even used to discover new proteins containing a PTM of interest. These
techniques utilized MALDI-TOF MS screening of a library of metabolically labeled cDNA
clones with motifs matching N-myristoylated proteins to determine which were most
susceptible to this PTM [72].
Some PTMs can be achieved in E. coli-based CFPS, but this application is generally
more technically challenging due to a lack of endogenous microsomes and the limited
number of PTMs possible in bacteria when compared to eukaryotes [64]. However,
utilization of E. coli remains advantageous in terms of overall protein yields and ease of
extract preparation, which have prompted the development of PTMs in this platform. The
open nature of the reaction enables users to tune redox conditions to make disulfide bond
formation feasible in this platform. Additionally some N-linked glycosylation has been
made possible through the supplementation of glycosylation machinery [73]. Glycosylation
was first achieved through the addition of purified glycosylation components after
completed cell-free translation, which was effective, but relatively time-consuming [74].
More recently, oligosaccharyltransferases have been synthesized in CFPS and shown to
be active in in vitro glycosylation without the need for purification [75]. Furthermore, E. coli
strains that have been optimized for glycoprotein synthesis have been used to prepare
cell-free extract, such that glycosylation can be pursued in a one-pot system [54].
Chinese hamster ovary extract contains endogenous microsomes, which provide
glycosyltransferases for glycoprotein synthesis, chaperones, and other molecules
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necessary for disulfide bridge formation [34]. Yeast has also been a platform of interest
for protein glycosylation, with glycosylation achieved when a completely homologous
system was used and yeast microsomes were added. However, yields in this platform are
much lower than in E. coli [76]. The wheat germ platform also requires exogenous
microsome addition, which has allowed for some PTMs to be incorporated [64,77]. A
human-based hybridoma-cell extract platform, similar to that of HeLa cell-based extracts,
was able to glycosylate human immunodeficiency virus type-1 envelope protein 120 [78].
1.1.3.2.3. High-Throughput Screening
The ability to achieve high-throughput protein production is a major advantage of
CFPS, as it enables rapid production and screening of a variety of protein products much
faster than in in vivo protein expression (Figure 1). Coupled CFPS allows for DNA
templates to be plugged in directly without the need for cell transformation/transfection,
and in some cases, assays of protein products can be done without the need for
purification, creating a powerful one-pot system [28]. A key application of high-throughput
CFPS is functional genomics, which allows for the elucidation of new genes and their
corresponding protein function. High-throughput screening can be pursued in any
platform, but most often utilizes E. coli, wheat germ, and rabbit reticulocyte extracts. Here
we will discuss some specific examples of CFPS for high-throughput applications.
The E. coli platform has been widely used and is well-developed, with relatively simple
extract preparation and high yields making it a prime candidate for high-throughput
synthesis (Table 2, Figure 2). One notable application of E. coli-based CFPS is the ability
to screen antibody mutant libraries in rapid design–build–test cycles for antibody
engineering. The best mutants could later be scaled up in the same platform for industrial
level synthesis (see Section 3.2.5, titled “Large-Scale”) [2]. Additionally, the E. coli platform
has been used for high-throughput functional genomics to identify numerous gene
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products involved in complex metabolic systems that result in protein accumulation and
folding in vitro [3].
While high-throughput applications commonly utilize E. coli, the eukaryotic wheat
germ platform has advantages for synthesis of soluble, active protein, making it better
suited for structural and functional analysis of certain proteins in CFPS [79]. The wheat
germ platform has shown the capacity to perform as a “human protein factory” when it was
utilized in an attempt to produce 13,364 human proteins. Using the versatile Gateway
vector system to generate entry clones allowed for successful synthesis of 12,996 of the
human proteins, with many displaying successful function [80].
CFPS from rabbit reticulocyte extract can also be used in a high-throughput fashion
for protein microarrays, in order to study protein function, interaction, and binding
specificity [81,82]. Ribosome and mRNA display technologies as well as in vitro
compartmentalization are also possible in the rabbit reticulocyte platform and allow for
genes to be linked to their protein products for functional genomic studies [83,84]. Lastly,
the Chinese hamster ovary platform is a candidate for high-throughput synthesis, but
examples of implementation have not been demonstrated to date [34,85].
1.1.3.2.4. Virus-Like Particles
Virus-like particles (VLPs) are capsids of viruses lacking genomic material, meaning
that they are a highly organized and symmetrical aggregations of proteins, capable of
carrying molecules of interest within them. As such, production of VLPs allows for study
of viral assembly, the creation of effective vaccines, drug delivery using encapsulation,
and materials science applications [86]. While VLPs can be produced in vivo, production
in CFPS platforms offers advantages including the ability to synthesize toxic VLPs and to
manipulate the redox conditions of the reaction for proper disulfide bond formation, which
may be essential for thermal stability [86]. The versatility of the CFPS reaction also allows
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for a single, more robust platform capable of producing many types of VLPs at scalable,
higher yields and with easier modification of reaction setup than would be possible in vivo
[87].
A variety of CFPS platforms have been used to produce many different VLPS,
including E. coli, HeLa, rabbit reticulocyte, and yeast. The E. coli platform has been used
to optimize disulfide bond formation in Q VLPs by expression without change to the redox
state of the reaction and subsequent exposure to diamide to form disulfide bonds postassembly, as VLP formation would occur naturally. The Q VLP has also been coexpressed with A2 protein, which naturally occurs in the full virus for infection and
competitive inhibition purposes [88]. Additionally, human hepatitis B core antigen was
produced by supplementation with disulfide forming agents glutathione and disulfide
isomerase [86]. MS2 bacteriophage coat proteins have also been expressed in high yields
using E. coli-based CFPS [87]. Both MS2 and Q VLPs have been produced with nonstandard amino acid enabled click chemistry, allowing proteins, nucleic acids, and polymer
chains to be attached to the surface of the VLPs [89]. In the last year, the E. coli platform
has enabled the production of the largest biological entities thus far in a CFPS platform:
fully functional T7 and T4 bacteriophages [90].
The HeLa cell-based CFPS platform has been used for poliovirus synthesis [91].
Rabbit reticulocyte CFPS has enabled viral assembly studies of HIV Gag protein
assembly, which forms immature but fully spherical capsids in CFPS [92]. Furthermore,
adenovirus type 2 fibers are able to self-assemble into trimers in rabbit reticulocyte CFPS
reactions and hepatitis C core proteins are able to form into capsids, which is not seen in
mammalian cell cultures [93,94]. The yeast platform has allowed for optimization of
translation of VLPs such as human papillomavirus 58 (HPV 58). Synthesis of this VLP
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through CFPS could enable the study of capsid assembly and encapsulation mechanisms
for HPV [95,96].
1.1.3.2.5. Large-Scale
The demonstrations of implementing CFPS from a high-throughput scale for
discovery to a manufacturing scale have expanded the utility of this platform [2,97]. Users
interested in leveraging this capacity for applications such as the production of antibodies
and industrial enzymes, as well as CFPS kit production for field or educational uses,
should consider the technical details of scaling up the entire workflow for CFPS (Figure
6). This begins with the capacity to scale cell growth, as well as scaling extract preparation.
Platforms that enable this scalability include E. coli, wheat germ, and rabbit reticulocyte
(Tables 1 and 2) [97–99]. The insect, yeast, and Chinese hamster ovary platforms may
also be amenable to scale-up in culture growth, as they are fermentable, but large-scale
extract preparation has not been well studied to date [100].
Next, platforms must have scalable CFPS reactions that maintain volumetric protein
yields even in large-scale reactions. E. coli CFPS has been shown to scale over many
orders of magnitude in batch format, from reactions as small as 10 µL to as large as 100
L [97]. Within this range of reaction sizes, volumetric protein yields remain constant if the
proper reaction vessel is used. For example, reactions up to 100 µL can be run in 1.5–2
mL microcentrifuge tubes, while reaction over 100 µL should be run in 24-well microtiter
plates or a similar thin-layer format [31,101,102]. For liter-scale reactions, bioreactors and
fermenters have been used [2,97]. The importance of vessel size for scale-up of batch
reactions is due in part to the need for proper oxygen exchange, such that increasing the
surface area to volume ratio of the reaction can significantly improve reaction yields
[31,102]. The scalability of the E. coli platform and discovery of cost-effective metabolisms
makes it well suited for industrial applications, as has been demonstrated by companies
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such as Sutro Biopharma, who use CFPS to produce large batches of antibodies in vitro
[103,104].
The wheat germ platform has been used for reaction scale-up through a robotic
discontinuous batch reaction that can perform reactions up to 10 mL in volume. This setup
is capable of producing at least 2 mg/mL of the protein of interest, including DCN1,
involved

in

ubiquitination,

human

sigma-1

receptor,

and

bacteriorhodopsin

transmembrane proteins. This system utilizes multiple cycles of concentration, feed buffer
addition, mRNA template addition, and incubation to achieve high protein yields with
minimized extract usage, an idea similar to continuous flow cell-free (CFCF) and
continuous exchange cell-free (CECF) [30,99]. CECF and CFCF formats may also be
used to scale up reaction size and increase protein yields as discussed in Section 2.3
“Batch, Continuous Flow, and Continuous Exchange Formats.” Continuous formats have
been pursued in Chinese hamster ovary, insect, E. coli, wheat germ, and yeast [30,32,34–
37]. Overall, the E. coli and wheat germ platforms are most amenable to large-scale
synthesis, as scale-up of the entire CFPS workflow has been demonstrated.
1.1.3.2.6. Membrane Proteins
The study of membrane proteins is an integral component of proteomics due to their
high abundance within organisms. Approximately 25% of all sequenced genes code for
hydrophobic proteins that integrate themselves into cell membranes [105]. Membrane
proteins serve a plethora of functions within cells including cell recognition, immune
response, signal transduction, and molecule transport. However, expressing these
complete proteins in vivo in their correct conformation often poses a challenge due to the
naturally low abundance during expression, high hydrophobicity, the necessity of
translocation into the membrane, and the impact to the host cell’s membrane integrity.
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CFPS platforms are able to circumvent these challenges by avoiding dependence on
the structural integrity of the cell membrane via the non-membrane bound system [106].
In addition, the supplementation of microsomes, vesicle-like structures, or the presence
of endoplasmic reticulum fragments during extract preparation (endogenous microsomes)
allows membrane proteins to correctly fold and incorporate themselves into these
structures during protein synthesis. Namely, the HeLa, Chinese hamster ovary, and insect
platforms all contain endogenous microsomes formed via rupturing of the endoplasmic
reticulum during extract preparation. These platforms have successfully expressed a
number of membrane proteins ranging from a two-transmembrane malarial protein
(HeLa), to epidermal growth factor receptor proteins (Chinese hamster ovary), and finally
to a KcsA potassium channel (insect) [39,107,108].
Platforms that require exogenous addition of microsomal structures for membrane
protein expression include rabbit reticulocyte, wheat germ, and E. coli. The rabbit
reticulocyte platform, with the supplementation of semipermeable cells, has been
demonstrated to properly express MHC class I heavy chain membrane proteins in their
correct conformations [109]. The wheat germ platform has successfully expressed human,
mouse, and mycobacterium desaturase complexes with the addition of liposomes, as well
as plant solute transporters, using a similar strategy [110,111]. The E. coli platform has
shown expression of a wide variety of membrane proteins including pores, channels,
transporters, receptors, enzymes, and others while utilizing the exogenous addition of
synthetic liposomes [106,112]
1.1.3.2.7. Difficult to Synthesize Proteins
The advantages of cell-free protein synthesis over in vivo protein synthesis, such as
the open reaction and absence of living cells, allow for the production of proteins that
would be difficult to manufacture in vivo due to the burden on the cell and inability to
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manipulate the environment of protein production (Figure 1). Such examples include
antibodies, large proteins, ice structuring proteins, and metalloproteins.
Other applications, such as expression of proteins from high GC content templates
(Section 3.3.2, titled “Streptomyces” and Section 3.3.7. titled “Pseudomonas putida”) and
thermostable proteins (Section 3.3.9, titled “Archaeal”), will be discussed in the low
adoption section.
1.1.3.2.7.1 Antibodies
The production of functional antibodies and antibody fragments in vitro using CFPS
has the potential to allow for simplification of the antibody production process for more
rapid manufacturing. This advantage is due in part to the open system, which can easily
be modified from case to case for the production of active antibodies using rapid design–
build–test cycles and modification of the redox potential of the reaction. Antibody
production has taken place in rabbit reticulocyte, E. coli, Chinese hamster ovary, wheat
germ, and insect platforms [100,113].
One of the first instances of antibody production in a CFPS platform was the synthesis
of the light chain of mouse Ig in rabbit reticulocyte [114]. Later on, the rabbit reticulocyte
platform was also used to synthesize the scFv-toxin fusion protein, which contains both
single-chain and gamma globulin antibodies [115,116].
Previous studies in E. coli have shown that protein disulfide isomerase for disulfide
bond shuffling is important for active antibody formation, while addition of DsbA, a thiol
disulfide oxidoreductase, does not improve active yield. This study also found that the
addition of chaperones helped to increase soluble yields but not functional yield [117].
Moreover, cell-free expression has been used to overcome low yields that occur in vivo
with rearrangement of variable regions [118]. In E. coli, synthesis of full-length correctly
folded and assembled antibodies has been accomplished in a range of scales. Fab
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antibodies have been produced with 250 µg/mL yields in reaction scales from 60 µL to 4
L, and scFv antibodies with yields up to 800 µg/mL in reaction scales from 10 µL to 5 L.
CFPS reactions containing iodoacetamide, protein disulfide isomerase, and both oxidized
and reduced glutathione are used to increase active yields. These yields were also
improved for industrial production by codon optimization, translation initiation optimization,
and temporal assembly optimization. This demonstrates the power of CFPS for antibody
production in industry as well as in screening and optimization [2]. The E. coli platform has
also allowed for the synthesis of IgG antibody drug conjugates using genetic code
expansion and iodoacetamide-treated extract supplemented with glutathione [119]. Other
antibodies including the Fab fragment of 6D9, scFv to Erb-2, and even gram per liter IgG
yields have been obtained in E. coli [120–122].
The Chinese hamster ovary platform has recently emerged as an easily optimizable
platform for high yield synthesis of monoclonal antibodies (mAbs). Using a commercially
available extract, successful synthesis of aglycosylated, active mAbs in yields greater than
100 g/mL has been accomplished. The process has been taken a step further by
exploring the utility of the platform for ranking yields of candidate antibodies [103].
Antibody production has also been achieved in wheat germ by lowering the concentration
of DTT in the reaction or by adding protein disulfide isomerase and oxidized and reduced
glutathione [123].
In the insect platform, which contains its own microsomes, adjustment of the redox
potential in the reaction by omitting DTT and including glutathione allowed for the creation
of antibody-enriched vesicles containing functional antibodies. This technique is notable
as it mimics synthesis of antibodies as it would occur in living cells and allows for the
vesicles and antibodies to be easily and efficiently separated from the CFPS reaction
[124]. Moreover, single-chain antibody fragments with non-standard amino acid
incorporation have been produced in the insect platform via translocation to microsomes
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[125]. Protein disulfide isomerase has also been supplemented to these reactions to yield
more active antibodies [62].
1.1.3.2.7.2 Large Proteins
The CFPS platform makes the synthesis of very large proteins more tractable in batch
mode, allowing for high quantity expression that would normally overwhelm in vivo
expression methods [6]. Successful synthesis of soluble, active proteins above 100 kDa
has been achieved within the E. coli, HeLa, insect, and rabbit reticulocyte platforms. With
the high protein producing efficiency of the E. coli platform (Figure 2), successful synthesis
of the first two (GrsA and GrsB1) of the five modules of a non-ribosomal peptide synthase
(NRPS) system was completed, both of which are greater than 120 kDa in size.
Specifically, these large proteins were synthesized in batch reactions that ran for 20 h and
generated yields of full-length, soluble GrsA at ~106 µg/mL and GrsB1 at ~77 µg/mL [126].
HeLa cell-based CFPS platforms have also demonstrated the ability to synthesize large
proteins ranging from 160 to 260 kDa. Namely, this platform produced the proteins GCN2
(160 kDa), Dicer (200 kDa), and mTOR (260 kDa) that were functionally validated with the
appropriate biochemical assays [127]. B-galactosidase (116 kDa) was successfully
synthesized within an insect platform [18]. The rabbit reticulocyte platform has proved to
successfully synthesize active kDa proteins >100, such as a cystic fibrosis
transmembrane conductance regulator of ~160 kDa [128].
1.1.3.2.7.3 Ice Structuring Proteins
Ice structuring proteins, or antifreeze proteins, are more niche, but still difficult-tosynthesize proteins that benefit greatly from CFPS. These proteins lack common structural
features as a family, are difficult to express in whole cells, and require validation of protein
products to ensure the active form is successfully produced. CFPS offers more rapid
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screening and production of both natural and engineered active ice structuring proteins.
Ice structuring proteins have been produced successfully in both insect and E. coli
platforms, and their activity can be tested without the need for purification through an ice
recrystallization inhibition assay [129].
1.1.3.2.7.4 Metalloproteins
Metalloproteins, such as [FeFe] hydrogenases and multicopper oxidases (MCOs), are
difficult to produce in vivo due to low yields, insolubility, poor metal cofactor assembly, and
oxygen sensitivity [130,131]. However, they have the potential to enable renewable
hydrogen fuel and other important biotechnological advancements. CFPS in the E. coli
platform has enabled the manipulation of reaction conditions with chemical additives for
the synthesis of soluble, active metalloproteins. Specifically, the use of post-CFPS CuSO4
addition for MCO production and the addition of maturation enzymes, iron, and sulfur for
[FeFe] reductases greatly improved active enzyme yields [130,131]. Additionally,
anaerobic growth of the extract source culture and anaerobic extract preparation were
necessary to produce active [FeFe] reductases [131]. The H-cluster of [FeFe]
hydrogenase has also been synthesized in E. coli CFPS through recreation of the
biosynthetic pathway and used to convert apo [FeFe] hydrogenase to active protein [132].
1.1.3.2.8. Miscellaneous Applications
CFPS has also been used for a number of miscellaneous applications, including
studies of translational machinery, genetic circuits, metabolic engineering, and genetic
code expansion. Many of these applications are more feasible and can be used more
rapidly in cell-free platforms than in vivo due to the open nature of the system, allowing for
faster design–build–test cycles and direct manipulation of the reaction (Figure 1).
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1.1.3.2.8.1 Studies of Translational Machinery
The open nature of CFPS and the lack of dependence on living cells enables the user
to study translational machinery in ways not possible in vivo. These include ribosomal
labeling, mutation of ribosomes, removal or replacement of some tRNAs, and generation
of orthogonal translation systems, which can improve our understanding of the process of
translation across species and help to enable a wider variety of genetic code expansion
options [6,133,134]. One such study piloted hybrid ribosome platforms, by supplementing
rabbit reticulocyte lysate with other mammalian ribosomes, to prevent energy consumption
not directed toward protein synthesis and to boost overall yields [135]. Another study
synthesized fully functional ribosomes via the integrated synthesis, assembly, and
translation (iSAT) platform [136]. This was achieved through in vitro rRNA synthesis and
assembly of ribosomes with supplemented E. coli ribosomal proteins. Functionality of
these ribosomes was demonstrated by the synthesis of active protein within a single CFPS
reaction [136].
1.1.3.2.8.2 Genetic Circuits
The challenge for researchers to understand the complexity of gene elements and
their interplay in an expedient manner is an ongoing task. Using CFPS for modeling such
genetic circuits to further understanding of the dynamics of genetic elements and to
program cells capable of executing logical functions provides numerous advantages over
in vivo approaches. These include (1) the control of gene and polymerase concentrations,
(2) quantitative and rapid reporter measurements, and (3) a larger parameter space that
can be evaluated in a high-throughput fashion [137,138]. E. coli, wheat germ, and yeast
platforms have all exhibited utility in modeling genetic circuits, with E. coli extracts being
the most widely used. Specifically, E. coli and wheat germ extracts have both modeled
one-, two-, and three-stage expression cascades within a genetic circuit assembly [139].
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E coli and yeast extracts have been used as genetic circuits to study the translational
noise within cells, determine kinetic parameters, and yield insights within the construction
of synthetic genetic networks [140]. Other E. coli genetic circuit studies have confirmed
and isolated cross talking events, derived a coarse-grained enzymatic description of
biosynthesis and degradation, and revealed the importance of a global mRNA turnover
rate and passive competition-induced transcriptional regulation among many other studies
[141–147].
1.1.3.2.8.3 Metabolic Engineering
The industrial demand for rapid development and screening of commodity chemicals
and natural products has prompted the adaptation of CFPS platforms for cell-free
metabolic engineering (CFME). This approach allows for a cost-effective platform to
produce large amounts of diverse products in a short amount of time [148]. Specifically,
CFME provides an in vitro platform comprised of catalytic proteins expressed as purified
enzymes or crude lysates that are capable of being mixed to recapitulate full metabolic
pathways [148]. The swift prototyping of this approach has already been employed to
generate a number of diverse products using yeast and E.coli-based platforms [149].
The power of this approach has been used for the production of bio-ethanol using a
yeast-based platform to circumvent the limitations of the conventional fermentation
process. By employing a bead-beating method to generate yeast cell extract, the CFPS
platform was able to generate 3.37 g/L of bio-ethanol compared to 4.46 g/L from the
fermentation process at 30 C. However, the CFPS platform excelled over the
fermentation platform at higher temperatures [150]. E. coli-based CFME has been
optimized for the metabolic conversion of glucose to 2,3-butanediol (2,3-BD) through the
engineering of an E. coli-based extract to (1) express the genes necessary to convert
pyruvate to 2,3-BD, (2) activate cell-free metabolism from glucose, and (3) optimize
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substrate conditions for highly productive cell-free bioconversions [151]. Additionally, E.
coli CFME has successfully produced a high titer of mevalonate through systematic
production of the enzymes involved in the mevalonate enzymatic pathway and
combinatorial mixing of the lysates along with the necessary substrates to recapitulate the
full mevalonate enzyme pathway in a biosynthetic manner [148]. Lastly, large NRPS
proteins produced in E. coli CFPS underwent identical crude lysate mixing approaches to
validate their functionality in a metabolic pathway and successfully produced a
diketopiperazine in a 12 mg/L concentration [126].
1.1.3.2.8.4 Genetic Code Expansion
Genetic code expansion allows for site-specific incorporation of non-standard amino
acids (nsAAs) into the protein of interest through reassignment of a codon. This is most
commonly achieved through stop codon suppression but can also be done through sense
codon reassignment, frameshift codons, or tRNA misacylation [152]. Co-production of an
orthogonal tRNA in CFPS has also allowed for nsAA incorporation [153]. Applications of
genetic code expansion include incorporation of biophysical probes for structural analysis
by NMR, MS, and more, incorporation of fluorophores for interrogation of local protein
structures, protein conjugation for production of biomaterials or protein immobilization,
incorporation of post-translational modifications, and usage of photocaged amino acids
for control of protein activity [152]. While genetic code expansion is possible in vivo, it
requires high concentrations of often expensive nsAAs in order to increase the intracellular
concentrations to levels high enough for faithful incorporation. The elimination of the
cellular barrier in CFPS allows much lower concentrations of nsAA to be used, which can
drastically reduce costs (Figure 1) [6,152].
Cell-free genetic code expansion has been accomplished in E. coli, insect, rabbit
reticulocyte, and wheat germ platforms. The most extensive variety of nsAA
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incorporations, from hydroxytryptophan to glycosylated serine, has been achieved in E.
coli [152]. The E. coli genome has even been recoded to lack the RF1 gene, and was then
capable of 40 incorporations of p-acetyl phenylalanine into an elastin-like polypeptide with
98% accuracy and a 96 µg/mL yield or a single incorporation into GFP with a yield of 550
µg/mL [31,154]. Moreover, suppression of two different stop codons, enabling the
incorporation of two different nsAAs into a single protein was achieved in vitro in this
platform [155]. One-pot protein immobilization reactions have also been constructed in E.
coli CFPS reactions, and are achieved using a combination of metal coordination, covalent
interactions, or copper-free click chemistry between the protein and activated agarose,
glass slides, beads, or silica nanoparticles [156]. This platform has even been used for
screening of new aminoacyl tRNA synthetases with adjusted substrate specificity to
improve incorporation of new nsAAs [119]. Furthermore, methylated oligonucleotides
were utilized to sequester tRNAs in active cell extract, allowing for sense codon
reassignment directly in the CFPS reaction. The oligo targets a sequence located between
the anticodon and variable loop of the tRNA, and is both generic for tRNA type and
species, allowing for one-pot sense codon reassignment in multiple cell-free platforms
[157]. Additionally, reactions utilizing the expanded genetic code have been prepared by
adding purified aminoacyl-tRNA synthetases and an orthogonal-tRNA template directly to
the reaction to prevent the need for unique extract preparations for different nsAA
incorporations [158].
CFPS allows for rapid screening of nsAA incorporation sites that can affect proper
protein folding and yields. Insect CFPS has been used to incorporate p-azido
phenylalanine, which was subsequently labeled with a fluorophore, for rapid screening of
candidate incorporation sites [152,159,160]. A variety of other nsAAs have also been
incorporated in insect, rabbit reticulocyte, and wheat germ platforms. A more in-depth list
of many nsAAs that have been incorporated in each platform can be found in
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“Cotranslational Incorporation of Non-Standard Amino Acids using Cell-Free Protein
Synthesis” [152].
1.1.3.3. Low Adoption Platforms
Cell-free platforms that have experienced low adoption thus far include those derived
from Neurospora crassa, Streptomyces, Vibrio natriegens, Bacillus subtilis, tobacco,
Arabidopsis, Pseudomonas putida, Bacillus megaterium, Archaea, and Leishmania
tarentolae (Figure 5). These platforms were characterized as low adoption platforms
because less than 25 papers have been published for each (Figure 5B). This section will
cover both platforms that were created years ago but have only been used for specialized
or limited applications, newly emerging platforms, and platforms that are experiencing a
revival after years with minimal usage. These platforms are generally less well optimized
and well-understood than those covered in the high adoption section, but may still be of
interest for certain applications or for further development. We have organized the
following based upon platform rather than application to give the reader an overview of
the landscape of applications that have been achieved in each platform. For platforms that
have not yet had published applications, proposed applications are discussed.
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Figure 5. Low adoption cell-free platforms and their applications. (A) Web of the
applications enabled by low adoption cell-free platforms. Connections shown are
based on applications that have been published or that have been proposed in
publications. Applications under “difficult to synthesize proteins” include high GC
content

proteins,

antimicrobial

peptides,

pharmaceutical

proteins,

and

thermophilic proteins. Miscellaneous applications include studies of translational
machinery, investigation of antibiotic resistance, genetic circuits, metabolic
engineering, and genetic code expansion. (B) Cumulative number of peerreviewed publications over the last 60 years for low adoption platforms. We have
used the metric of cumulative publications to indicate which platforms are less
utilized and have categorized platforms with under 25 papers as low adoption
platforms. These data were generated by totaling papers from a PubMed Boolean
search of the following: (“cell free protein synthesis” OR “in vitro transcription
translation” OR “in vitro protein synthesis” OR “cell free protein expression” OR
“tx tl” OR “cell-free translation”) AND “platform name.” The platform name used
for each search corresponds to the name listed in the graph’s key. While this
metric is an indicator of the level of adoption for each platform, it does suffer from
inconsistencies due to irrelevant search results, such as papers reporting studies
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in which the researchers produce proteins from the organism of interest rather
than from cell extract derived from the organism. This inconsistency was
significant for platforms with fewer papers, so we pursued data curation to remove
irrelevant papers and add in missing papers. This information was collected on
23 December 2018, and curated search results for each platform can be found in
Supplemental Information, where red indicates that the paper was removed from
the search results and green indicates that the paper was added to the search
results.
1.1.3.3.1. Neurospora crassa
A platform utilizing Neurospora crassa was created with interest in developing it as a
platform for which many gene deletion mutants exist [161]. This was proposed as a way
to better study translational quality control utilizing the mutant strains available. This
platform has been used to characterize the importance of 7-methylguanosine caps,
determine locations of ribosome binding sites, investigate the importance of heat shocking
cell cultures and prepared mRNA templates, determine kinetics of luciferase synthesis,
and incorporate fluorescent nsAAs to investigate ribosomal stalling [162–167].
1.1.3.3.2. Streptomyces
Streptomyces was first used in the 1980s for coupled reactions to express proteins
from both linear and circular recombinant Streptomyces plasmids, but the original platform
fell out of use in the 1990s, likely due to the time-consuming preparation and low yields of
the platform [168,169]. Recently, the Streptomyces platform has been revived with
simplified extract preparation and some improvements to protein yield [15,168]. The
platform was optimized with the intention of use for expressing high GC content templates
to enable production of natural gene clusters in vitro. With new genome mining
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technologies, knowledge of natural product gene clusters is increasing rapidly. However,
in vivo expression of these clusters results in very low soluble yields due to the high
metabolic burden on cells [168]. Streptomyces-based CFPS not only accounts for codon
optimization for higher GC content templates, but also presents an opportunity for
improving soluble expression of natural product gene clusters [15,168]. Examples of high
GC content gene expression include tbrP, tbrQ, and tbrN for nonribosomal peptides
synthesis of tambromycin as well as the TEII gene involved in valinomycin synthesis [168].
While the Streptomyces platform does significantly improve solubility of these proteins
compared to expression in E. coli CFPS, it does suffer from diminished yields overall,
indicating that further optimization of the platform is necessary [168].
1.1.3.3.3. Vibrio natriegens
Within the last year, the Jewett, Church, and Siemann-Herzberg laboratories have
each separately developed a CFPS platform based upon Vibrio natriegens [10,170,171].
With its doubling time being the shortest of all known organisms, its high rate of protein
synthesis, and high metabolic efficiency, this platform has potential to be an ideal
candidate for CFPS [170]. In addition to its unique doubling time, Vibrio natriegens extract
preparation requires a stationary phase harvest for the highest translational efficiency in
a CFPS platform. Typically, CFPS extracts are harvested in a tight window during the midexponential phase to maximize translational efficiency. However, the Vibrio natriegens
extract allows a great amount of flexibility for the user to “set and forget” the culture for a
stationary phase harvest where ribosome production is thought to be lowest among other
microorganisms [10].
Another advantage to extract preparation for this platform is its high resistance to
damage via over-lysis. Additionally, it is relatively agnostic to lysis buffer resuspension
volume. Together, these allow for inexperienced CFPS users to easily generate robust
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extract [10]. In addition, the V. natriegens platform generates a very high volume of extract
compared to the standard E. coli platform, allowing for 8–12 mL of active lysate per L of
culture compared to just 1–3 mL/L for E. coli when grown in shake flasks and lysed by
sonication [10]. V. natriegens extract has even been shown to maintain 100% of activity
after one week of storage at room temperature post-lyophilization in the presence of
trehalose [10]. Although this platform appears to be promising in terms of flexibility and
scale of extract preparation, very few applications have been proposed. Aside from
reporter proteins being expressed, the Jewett laboratory has demonstrated the successful
synthesis of a series of antimicrobial peptides using this platform [10].
1.1.3.3.4. Bacillus subtilis
The development of a Bacillus subtilis CFPS platform has not been pursued until
recently due to requirements of exogenous mRNA addition, protease inhibitors, DNase
treatments, and less efficient energy systems, as determined by studies in the 1970s and
1980s. These early studies utilized B. subtilis extracts to study various antibiotic
resistances, investigate bacterial ribosome and mRNA specificity, and identify plasmid
replication control genes [172–174]. In the last few years, the Freemont laboratory has
developed a standardized workflow that circumvents the limitations of the past B. subtilis
platform. By using a 3-phosphoglycerate (3-PGA) energy regeneration system, with
optimized magnesium and potassium glutamate concentrations based upon the E. coli
CFPS platform, the Freemont laboratory has created a Bacillus WB800N platform capable
of expressing 0.8 μM GFPmut3b in a reaction that can last for several hours. More
research is needed on this platform to reach expression levels seen within the E. coli
platform, but the Freemont laboratory has successfully characterized an inducible
expression platform that was able to quantify the activity of Renilla luciferase. Proposed
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applications for this platform include the production of industrial or pharmaceutical proteins
and applications in metabolic engineering [16].
1.1.3.3.5. Tobacco
Though a relatively undeveloped platform, tobacco does allow for a few specific
applications and is one of the few plant-based platforms. In the past decades, various
parts of the tobacco plant, such as leaves, terminal buds, and trichomes, have been used
to prepare extract [175–178]. These extracts were then used to elucidate differences
between 70S and 80S ribosomes, understand synthesis of indoleacetic acid, diterpene
cis-abienol, and cytokinins, study cauliflower mosaic virus transcription, and determine
nicotine N-demethylase activity [176–181]. More recently, tobacco BY-2 cells have
emerged as the source of extract. Preparation of up to 100 mL of cell extract from BY-2
suspension cultures is possible for larger scale applications [12]. Moreover, successful
tobacco extract preparation requires only 4–5 h, whereas other eukaryotic platforms range
from 1–5 days (Table 2) [64]. The BY-2 platform has enabled further investigation into
positive strand RNA genomes from plant viruses, through synthesis of tomato bushy stunt
virus, tomato mosaic virus, brome mosaic virus, and turnip crinkle virus [182,183].
Replicases formed from viral RNAs in CFPS are able to bind to the microsomal structures
contained in the extract, allowing for elucidation of the mechanism of genome replication
by these viruses, and for the screening of viral mutations [182,183].
Tobacco extract also enables some post-translational modifications, disulfide bond
formation, and membrane protein synthesis. The production of a full size, active glucose
oxidase antibody and a transmembrane protein has been achieved in this platform without
microsomal addition, showing that the extract does contains active endogenous
microsomal units that allow for disulfide bond formation, glycosylation, and co-translational
membrane integration [12]. However, the full extent of possible PTMs in tobacco CFPS is
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not well understood. High-throughput coupled reactions from PCR templates with
phosphorothioate-modified oligonucleotides have also been created with tobacco extract
[12].
1.1.3.3.6. Arabidopsis
An Arabidopsis-based platform was created in 2011, with the proposed advantage of
applying the vast knowledge of Arabidopsis genetics in combination with CFPS to study
post-transcriptional regulation [184]. However, this platform has seen limited actualization
of applications, with brief work done on the degradation of uncapped mRNA in mutant cell
lines and some investigation into ribosome stalling [184].
1.1.3.3.7. Pseudomonas putida
Serving as a model organism and understood well at the biochemical level, the Gramnegative bacterium Pseudomonas putida has been well established for laboratory
research and industrial production of biofuels, recombinant antibody fragments, and
natural products. With this already well-established research framework at hand, the
Jewett Laboratory has developed and optimized the P. putida CFPS platform capable of
synthesizing approximately 200 µg/mL of reporter protein within a 4 h, 15 µL batch
reaction. Extract preparation for this platform was previously reported, based on that of
the E. coli platform with slight modifications. Overall, preparation of P. putida is faster and
less laborious than the Streptomyces platform, and is hypothesized to be useful for
prototyping the expression of GC-rich genes with codon usage bias. As another high GC
bacteria, P. putida may be chosen over the Streptomyces platform for its aforementioned
ease of extract preparation. Moving forward, this platform may also prove useful in
screening gene regulatory elements, as well as closing the gap between in vitro and in
vivo prediction [14].
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1.1.3.3.8. Bacillus megaterium
In addition to the Bacillus subtilis platform, the Freemont laboratory has also begun
to pilot a CFPS platform for Bacillus megaterium, a large Gram-positive bacterium with
potential biotechnology applications including the production of penicillin G amidase, Bamylases, and vitamin B12. Unlike the well characterized Bacillus subtilis bacterium
species, B. megaterium has remained a relatively uncharacterized microbe due to its lowefficiency and time-consuming protoplast transformation procedure. However, creating a
CFPS platform to study B. megaterium provides some major advantages over B. subtilis
due to its (1) stable plasmid maintenance, (2) minimal neutral alkaline protease activity,
and (3) ability to metabolize low-cost substrates. Currently, this CFPS platform has been
used to prototype genetic elements and has demonstrated a protein titer of about 70
g/mL [185] (Figure 2).

1.1.3.3.9. Archaeal
Various archaeal hyperthermophiles and methanogens have been utilized to generate
new CFPS platforms, including Methanobacterium formicicium, Methanosarcina barkeri,
Methanococcus vannielii, Thermus Thermophilus, Sulfolobus tokodaii, Sulfolobus
solfataricus, and Thermococcus kodakarensis.
The thermophilic organisms S. solfataricus and T. kodakaraensis have been utilized
in CFPS for expression of thermophilic proteins, which can be difficult to synthesize in
vivo. Ribosomes isolated in cell extracts from these strains are capable of performing at
higher temperatures, allowing CFPS reactions to be run at higher temperatures (75 °C for
S. solfataricus; 65 °C for T. kodakaraensis) for improved folding of thermophilic proteins
[20,186]. However, other problems with high-temperature CFPS reactions have yet to be
fully mitigated. For example, production of chitinase in T. kodakarensis CFPS stopped
after 30 min, which was conjectured to be an issue with energy depletion worsened by the
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shorter half-life of energy-rich molecules at high temperatures [20]. Additionally, coupled
reactions are not yet feasible at elevated temperatures, due to the differences in optimal
performance temperatures for transcription and translation reactions [20].
Many archaeal methanogenic CFPS platforms have also been used to probe
antibiotic sensitivity in order to elucidate phylogenetic connections. Antibiotic targeting to
ribosomes can be confirmed using CFPS platforms in a way not possible in vivo because
cell viability is inconsequential [187]. Antibiotic enhancement of neomycin and
paromomycin and the physiological roles of polyamines were also investigated in T.
thermophilus and S. tokodaii CFPS platforms [188,189].
1.1.3.3.10. Leishmania tarentolae
Leishmania tarentolae, a protozoan platform, is a relatively new platform that has
experienced some recent optimization. L. tarentolae appears to be particularly promising
for growth and extract scalability, with a relatively short doubling time and faster extract
preparation when compared to eukaryotes of interest [190].
L. tarentolae-based CFPS has been utilized for a variety of high-throughput
applications, with CFPS possible directly from PCR templates and protein analysis
possible directly in the reaction mixture. One type of analysis utilizes fluorescence crosscorrelation spectroscopy to analyze protein–protein or protein–small-molecule interactions
[11,190]. Protein arrays can also be constructed in time and cost-effective ways in the L.
tarentolae platform by utilizing “translation and immobilization of protein on hydrophobic
substrate” (TIPoHS). Here, CFPS reactions are run on membranes, and immobilization
and detection are achieved via a c-terminal GFP tag [191].
The L. tarentolae platform has been used for disulfide bond formation, and while other
PTMs may be possible, they are not yet well defined or understood [64,192]. The platform
is also capable of membrane protein synthesis with the addition of liposomes or
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nanodiscs, and was used to synthesize 22 different human solute carrier proteins [193].
Along with E. coli, methylated oligonucleotides have been used to sequester tRNAs for
one-pot sense codon reassignment, allowing for genetic code expansion in L. tarentolae
[157].
1.1.3.4. Recent and Future Applications
An incredible diversification of CFPS usage has occurred since its inception in 1961.
In the last three years alone, there have been a handful of key new applications that have
contributed greatly to the field of CFPS. These include the first instances of CFPS used
for education, for the development of one-pot reactions for glycoprotein synthesis, for
sense codon reassignment, for protein immobilization, for continued refinement of
lyophilization for better shelf stability of cell-free extract, and for the demonstration of
multiple
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amino

acid

incorporations

into

a

single

protein

[43,46,47,53,54,154–157]. Furthermore, a handful of promising new and revived CFPS
platforms

from

Streptomyces,

Pseudomonas putida,

Bacillus

subtilis,

Bacillus

megaterium, and Vibrio natriegens have been introduced for novel applications, including
the synthesis of proteins from high GC templates (Streptomyces; P. putida), and for the
further development of applications such as metabolic engineering (B. subtilis) [10,14–
16,168,170,171].
Despite the proliferation of CFPS platforms and applications in the last 60 years, there
are still many new directions in which the technology can be taken. Some future directions
for CFPS may include further development and optimization of current platforms,
especially the emerging or re-emerging platforms of Streptomyces, Pseudomonas,
Bacillus subtilis, Bacillus megaterium, and Vibrio natriegens. Soon, the proposed
applications of these platforms may be actualized. Furthermore, we may see additional
CFPS platforms be established to solve new problems or to fill other existing gaps that
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current platforms have left. In terms of applications, there may be more utilization of CFPS
for education, metabolic engineering, personalized medicine, and diagnostics, as current
work seems to have only scratched the surface of these applications. Further development
of large-scale CFPS may also be a future direction developed alongside these applications
in order to support new industrial endeavors.
1.1.4. Methodological Differences between Platforms
While the user’s selection of a given CFPS platform will be primarily driven by the
applications enabled by a platform, there are often multiple platforms that can be used for
a single type of application. The choice between these platforms can be guided by factors
including the accessibility and technical complexity of the methods used to produce the
cell extract, the reagents used for CFPS reactions, the type of reaction (coupled vs
uncoupled), and the productivity of the platform. Here we provide further guidance to the
user in choosing the platform that best suits their needs, and simplify the effort needed to
make this choice by providing a condensed methodological comparison of the high
adoption cell-free platforms: E. coli, insect, yeast, Chinese hamster ovary, rabbit
reticulocyte lysate, wheat germ, and HeLa cells (Tables 1–3).
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Figure 6. General workflow for preparation of cell-free extract and set up of CFPS
reactions. A visualization from cell growth to the CFPS reaction is depicted above
for a new user, highlighting the main steps involved.
1.1.4.1. Productivity
Firstly, different platforms will be better suited for the production of different proteins
of interest, and maximizing protein yields is not required for all applications. Therefore,
matching the application with a platform’s productivity will enrich success for new users
(Figure 2). For example, industrial level protein production is currently best enabled by E.
coli or wheat germ platforms, with possibilities of large-scale protein production in the
emerging Vibrio natriegens and Pseudomonas putida platforms (Figures 4 and 5).
However, for many applications that may not require large protein samples, such as smallscale assays or functional investigations, most possible platforms would still provide large
enough yields. In general, eukaryotic platforms give lower protein yields, with the
exception of the wheat germ platform (Figure 2). On the lowest end of the productivity
scale are the rabbit reticulocyte and archaeal platforms, which produce under 20 µg/mL
of protein in batch format (Figure 2). Overall, it is important to choose a platform that is
suited to producing the protein of interest in the quantity necessary for the desired
application.

42

1.1.4.2. Growth
Methodology for cell growth from representative sources for each high adoption
platform is summarized in Table 1. Growth media is highly variable between platforms, as
would be expected even in in vivo protein expression. Additionally, cells can be grown in
a variety of vessels, from baffled flasks in an incubator for wheat germ and E. coli to
fermenters and spinner flasks for insect, Chinese hamster ovary, and HeLa cells. The
vessel choice may also depend on the growth scale desired. Lastly, cell cultures must be
harvested, which is typically done via centrifugation and washing of the pelleted cells.
Platforms that stand out most due to specialized methods are wheat germ and rabbit
reticulocyte. In general, all other platforms utilize cell growth in liquid culture, centrifugation
for the harvest of cells, and pellet washing in an HEPES-based buffer supplemented with
acetate salts and with DTT in some cases. However, for wheat germ, wheat seeds are
ground in a mill and sieved, and embryos are selected by solvent flotation [194]. Rabbit
reticulocyte extract preparation may even require treatment of live rabbits to make them
anemic as well as bleeding of the rabbits to obtain the cells needed [98].
Table 1. Comparison of growth methods for high adoption platforms. We have
assembled the major growth methodologies for each of the high adoption
platforms to give users an idea of the relative differences between them. These
are not the only techniques that have been used for growth for each platform, but
they are generally representative of the methods.
Growth
Platform

E. coli

Media/Vessel
Media: 2× YPTG (5 g NaCl, 16 g
Tryptone, 10 g Yeast extract, 7 g
KH2PO4, 3 g KHPO4, pH 7.2/750
mL solution, 18 g Glucose/250 mL
solution).
Vessel: 2 L Baffled Flask.
Conditions: 37 C, 200 RPM

Harvest

Key Citations

When OD600 is 3 ,centrifuge at 5000× g for 10
min at 10 C. Wash pellet with 30 mL S30
buffer (10 mM Tris OAc, pH 8.2, 14 mM
Mg(OAc)2, 60 mM KOAc, 2 mM DTT), then
centrifuge at 5000× g for 10 min at 10 C.
Repeat wash 3 times in total.

[22]
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Wheat Germ

Grind wheat seeds in a mill.

Yeast

Media: 2% w/v Peptone, 1% w/v
Yeast extract, 2% w/v Glucose
Vessel: 2.5 L baffled flask
Conditions: 30 C, 250 RPM

Rabbit
Reticulocyte

Make rabbits anemic over 3 days
by injections of APH.

Insect

HeLa

Chinese
Hamster
Ovary

Media: Animal component free
insect cell medium.
Vessel: Fermentor.
Conditions: 27 C
Media: Minimal essential medium
supplemented with 10% heatinactivated fetal calf serum, 2 mM
glutamine, 1 U/mL penicillin, 0.1
mg/mL streptomycin.
Vessel: Spinner flask with cell
culture controller
Conditions: 37 C, pH 7.2, 67 ppm
oxygen, 50 RPM
Media: Power Chinese hamster
ovary-2 chemically defined serumfree media
Vessel: Fermentor
Conditions: 37 C

Sieve through 710–850 mm mesh, select
embryos via solvent flotation method using a
solvent containing 240:600 v/v cyclohexane
and carbon tetrachloride. Dry in fume hood
overnight.
When OD600 of 10–12 is reached, centrifuge
culture for 10 min at 3000× g. Wash pellet with
Buffer A (20 mM HEPES, pH 7.4, 100 mM
KOAc, 2 mM Mg(OAc)2). Centrifuge for 10 min
at 3000× g and 4 C. Repeat washing 3 times.
Bleed rabbits on day 8. Filter blood through
cheesecloth and keep on ice, then centrifuge at
2000 RPM for 10 min.
When cell density reaches 4 × 106 cell/mL,
centrifuge culture at 200× g for 10 min. Wash
once with buffer (40 mM HEPES KOH, pH 7.5,
100 mM KOAc, 4 mM DTT).

[194]

[19]

[98]

[129]

Harvest when cell density reaches 0.7–0.8 ×
106 cells/mL. Wash 3 times with buffer (35 mM
HEPES KOH, pH 7.5, 140 mM NaCl, 11 mM
glucose).

[13]

Harvest at 2 × 106 cells/mL cell density by
centrifuging at 200× g for 10 min. Wash cells
once with buffer (40 mM HEPES KOH, pH 7.5,
100 mM NaOAc, 4 mM DTT).

[17]

1.1.4.3. Extract Preparation
Extract preparation consists of pre-lysis preparation, lysis, and post-lysis processing,
which are covered in detail for each high adoption platform in Table 2. Lysis methods not
only vary from platform to platform, but many different lysis methods can also be used for
a single platform. Here we have highlighted just one of the methods used for each
platform, but others may also be viable. Firstly, cells are resuspended, then sonication (E.
coli, wheat germ), homogenization (yeast), nitrogen cavitation (HeLa, insect), freeze-thaw
(insect), syringing (Chinese hamster ovary), osmotic lysis (rabbit reticulocyte), or other
lysis methods may be used to disrupt cell membranes. The lysate is centrifuged at high
speeds to separate out cell membrane fragments and other unnecessary cellular debris.
Post-processing after lysis and centrifugation also varies from platform to platform. For
example, a run-off reaction, where the supernatant is incubated, is performed on E. coli
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extract. For Chinese hamster ovary, HeLa, insect, wheat germ, and yeast, desalting or
dialysis is performed on the supernatant. The Chinese hamster ovary, HeLa, and rabbit
platforms are generally treated with micrococcal nuclease to degrade remaining
endogenous mRNA in the extract, and the nuclease activity is quenched through addition
of EGTA. All extracts are then flash frozen in liquid nitrogen and stored either in liquid
nitrogen, or more frequently at −80 °C if CFPS is not immediately performed afterwards.
Table 2. Comparison of extract preparation methods for high adoption platforms.
We have assembled the major extract preparation methodology for each of the
high adoption platforms to give users an idea of the relative differences between
them. These are not the only techniques that have been used for extract
preparation for each platform, but they are generally representative of the
methods.
Extract Prep
Platform

Pre-Lysis

E. coli

Resuspend in 1
mL/1 g pellet of
S30 buffer by
vortexing.

Wheat Germ

Wash 3 times
with water
under vigorous
stirring to
remove
endosperm.

Lysis

Post-Lysis Processing

Growth and
Prep Time

Key
Citations

Sonicate on ice for 3
cycles of 45 s on, 59
s off at 50%
amplitude. Deliver
800–900 J total for
1.4 mL of
resuspended pellet.
Supplement with a
final concentration of
3 mM DTT.
Sonicate for 3 min in
0.5% Nonidet P-40.
Wash with sterile
water. Grind washed
embryos into fine
powder in liquid
nitrogen and
resuspend 5 g in 5mL
of 2× Buffer A (40
mM HEPES, pH 7.6,
100 mM KOAc, 5 mM
Mg(OAc)2, 2 mM
CaCl, 4 mM DTT, 0.3
mM of each of the 20
amino acids).

Centrifuge lysate at 18,000× g
and 4 C for 10 min. Transfer
supernatant while avoiding
pellet. Perform runoff reaction
on supernatant at 37 C and
250 RPM for 60 min. Centrifuge
at 10,000× g and 4 C for 10
min. Flash freeze supernatant
and store at −80 C.

1–2 days

[22]

Centrifuge at 30,000× g for 30
min. Filter supernatant through
G-25 column equilibrated with
Buffer A. Centrifuge column
product at 30,000× g for 10 min.
Adjust to 200 A260/mL with
Buffer A. Store in liquid nitrogen.

4–5 days

[64,194]
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Yeast

Resuspend
cells in 1 mL
lysis buffer (20
mM HEPES
KOH, pH 7.4,
100 mM KOAc,
2 mM
Mg(OAc)2, 2
mM DTT, 0.5
mM PMSF) per
1 g cell pellet.

Pass through
homogenizer once at
30,000 psig.

Rabbit
Reticulocyte

Resuspend
cells in
buffered saline
with 5 mM
glucose, then
centrifuge at
2000 RPM for
10 min. Repeat
wash 3 times.

Resuspend cells in
1.5 times the packed
cell volume of icecold water, mix
thoroughly.

Insect

Resuspend
cells in buffer
to final density
of 2 × 108
cells/mL.

Mechanically lyse
cells by rapidly
freezing in liquid
nitrogen, then
thawing in water bath
at 4 C or use a
disruption chamber
with 20 kg/cm2
nitrogen gas for 30
min.

HeLa

Resuspend in
extraction
buffer (20 mM
HEPES KOH,
pH 7.5, 135
mM KOAc, 30
mM KCl, 1.655
mM Mg(OAc)2)
to ~2.3 × 108
cells/mL.

Chinese
Hamster
Ovary

Resuspend
cells in buffer
to density of 5
× 108 cells/mL.

Centrifuge homogenate at
30,000× g for 30 min at 4 C.
Then repeat centrifugation with
supernatant in a spherical
bottom bottle. Desalt
supernatant in dialysis tubing
with 4 exchanges of 50× volume
lysis buffer for 30 min each at 4
C. Centrifuge at 60,000× g for
20 min at 4 C. Flash freeze and
store at −80 C.
Spin lysate at 15,000× g for 20
min at 2 C. Pour supernatant
though 53 m nylon. Treat with
micrococcal nuclease by adding
0.2 mL of 1 mM hemin, 0.1 mL
of 5 mg/mL creatine kinase, 0.1
mL of 0.1 M CaCl2, 0.1 mL of
micrococcal nuclease. Incubate
at 20 C for 15 min, then add
0.1 mL of 0.2 M EGTA and 60
L of 10 mg/mL tRNA. Store in
liquid nitrogen or at −70 C.

1–2 days

[19,195]

~8 days to
treat rabbits,
1 day for
extract
preparation

[98]

Centrifuge lysate at 10,000× g
for 10 min. Apply supernatant to
G-25 gel filtration column. Pool
fractions with highest A260, flash
freeze in liquid nitrogen and
store at −80 C.

1–2 days

[18,129,1
95,196]

Disrupt cells via 1
MPa nitrogen
pressure for 30 min in
a cell disruption
chamber.

Centrifuge homogenate at
10,000× g for 5 min at 4 C.
Pass supernatant through a PD10 desalting column equilibrated
with extraction buffer. Treat 100
L of extract with 1 L of 7500
U/mL nuclease S7 and 1 L of
100 mM CaCl2 for 5 min at 23
C, then add 8 L of 30 mM
EGTA. Flash freeze eluted
extract in liquid nitrogen and
store at −80 C.

1–2 days

[13,195]

Disrupt cells by
syringing the pellet
through a 20-gauge
needle.

Centrifuge lysate at 10,000× g
for 10 min. Apply supernatant to
G-25 gel filtration column. Pool
fractions with an A260 above
100. Treat pooled fractions with
10 U/mL S7 nuclease and 1 mM
CaCl2, incubate at room
temperature for 2 min, then add
6.7 mM EGTA. Flash freeze in
liquid nitrogen and store at −80
C.

1–2 days

[17]
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1.1.4.4. CFPS Reaction Setup
CFPS reaction setup requires mixing of many reagents to initiate protein synthesis,
and the details of setup for each high adoption platform are covered in Table 3. There are
two main differences among CFPS setups: the chosen energy system and whether the
reaction is coupled or uncoupled. Otherwise, the reaction components are generally the
same, with two unique reagents used for each platform and slight variations in
concentration from platform to platform. Common reagents include ATP, GTP, UTP, CTP,
tRNA, HEPES, Mg salts, K salts, 20 amino acids, and energy rich molecules. Most
platforms use a creatine phosphate/creatine kinase energy system, and the most work
has been done in E. coli to enable more inexpensive energy systems, such as PEP,
glucose, and maltodextrin [8,197]. Reaction temperature has also been a major point of
optimization for each of these platforms, with typical temperatures ranging from 21 to 37
°C among the various platforms [17,195,198] (Table 2). In terms of reaction type, coupled
reactions are desirable because of the ease of setup, but uncoupled reactions are typically
used for eukaryotic platforms to improve yields (see Section 2.2, titled “Coupled and
Uncoupled Formats”) [28]. Uncoupled reactions require an in vitro transcription reaction
often catalyzed by T7 RNA polymerase (T7RNAP), followed by mRNA purification, then a
cell-free translation reaction utilizing the prepared lysate, and are both more timeconsuming and more difficult in terms of handling. Platforms that generally utilize
uncoupled reactions include wheat germ, rabbit reticulocyte, insect, and HeLa.
Transcription for most platforms that utilize coupled reactions require T7RNAP, but some
platforms, such as E. coli are able to employ solely the endogenous polymerase [199,200].
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Table 3. Comparison of cell-free protein synthesis reaction setup for high
adoption platforms. This table is intended to help users understand major
differences between setups for various high adoption platforms, namely whether
reactions are generally coupled or uncoupled, what energy systems are typical,
and what temperatures the reactions are run at. These are not the only setups
that have been used for successful cell-free protein expression in each platform,
but they are generally representative of the reagents, concentrations, and
temperatures used for each platform.

Platform

Vessel/Conditions

E. coli

Vessel: Many vessels
can be used, yield
increases as the
surface area to
reaction volume ratio
increases Conditions:
30 C overnight or 37
C for 4 h

Wheat
Germ

Vessel: Not noted
Conditions: 26 C

Yeast

Vessel: 15 L
reactions in 1.5 mL
microfuge tubes
Conditions: 21 C

Cell-Free Protein Synthesis Reaction
Reaction Composition
33% v/v E. coli extract, 16 g/mL
T7RNAP, 16 ng/mL DNA template,
Solution A (1.2 mM ATP, 0.85 mM
GTP, 0.85 mM UTP, 0.85 mM CTP,
31.50 g/mL Folinic Acid, 170.60
g/mL tRNA, 0.40 mM Nicotinamide
Adenine Dinucleotide (NAD), 0.27 mM
Coenzyme A (CoA), 4 mM Oxalic
Acid, 1 mM Putrescine, 1.50 mM
Spermidine, 57.33 mM HEPES buffer),
Solution B (10 mM Mg(Glu)2, 10 mM
NH4(Glu), 130 mM K(Glu), 2 mM of
each amino acid, 0.03 M
Phosphoenolpyruvate (PEP))
First, perform an in vitro transcription
reaction and isolate mRNA using SP6
RNA polymerase. Set up cell-free
translation as follows: 24% v/v wheat
germ extract, 4 mM HEPES KOH, pH
7.8, 1.2 mM ATP, 0.25 mM GTP, 16
mM creatine phosphate, 0.45 mg/mL
creatine kinase, 2 mM DTT, 0.4 mM
spermidine, 0.3 mM of each of the 20
amino acids, 2.5 mM Mg(OAc)2, 100
mM KOAc, 50 g/mL deacylated tRNA
from wheat embryos, 0.05% Nonidet
P-40, 1 M E-64 as proteinase
inhibitor, 0.005% NaN3, 0.02 nmol
mRNA.
25 mM HEPES KOH, pH 7.4, 120 mM
K(Glu), 6 mM Mg(Glu)2, 1.5 mM ATP,
2 mM GTP, 2 mM CTP, 2 mM UTP,
0.1 mM of each of 20 amino acids, 25
mM creatine phosphate, 2 mM DTT,
0.27 mg/mL creatine phosphokinase,
200 U/mL RNase Inhibitor, 27 g/mL
T7 RNAP, DNA template, and 50% v/v
yeast extract
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Key Citations

PEP, glucose +
glutamate
decarboxylase, or
maltodextrin are
possible

[22,201]

Creatine
phosphate +
creatine kinase

[194]

Creatine
phosphate +
creatine kinase

[19,195]

Rabbit
Reticulocyte

Vessel: 200 L
reaction performed in
an NMR spectrometer
Conditions: 30 C

Insect

Vessel: 25 L reaction,
vessel size not noted
Conditions: 25 C

HeLa

Vessel: 6 L reaction,
vessel not noted
Conditions: 32 C, 1 h

Chinese
Hamster
Ovary

Vessel: 25 L reaction,
vessel size not noted
Conditions: 33 C, 500
RPM shaking in
thermomixer

First, perform an in vitro transcription
reaction and isolate mRNA using T7
RNAP. Supplement 1 mL of rabbit
reticulocyte lysate with 25 M hemin,
25 g creatine kinase, 5 mg
phosphocreatine, 50 g of bovine liver
tRNAs, and 2 mM D-glucose. Initiate
in vitro translation by combining 27 nM
of in vitro transcribed mRNAs, 50% v/v
supplemented lysate, 75 mM KCl,
0.75 mM MgCl2, and 20 M amino
acids mix.
First, perform an in vitro transcription
reaction and isolate mRNA using T7
RNAP. Then set up cell-free
translation as follows: 1.5 mM
Mg(OAc)2, 0.25 mM ATP, 0.1 mM
GTP, 0.1 mM EGTA, 40 mM HEPES
KOH, pH 7.9, 100 mM KOAc, 20 mM
creatine phosphate, 200 g/mL
creatine kinase, 2 mM DTT, 80 M of
each of the 20 amino acids, 0.5 mM
PMSF, 1 U/µL RNase inhibitor, 200
g/mL tRNA, 320 g/mL mRNA, and
50% v/v insect cell extract. Addition of
20% v/v glycerol to the reaction was
also shown to improve yields.
First, perform an in vitro transcription
reaction and isolate mRNA using T7
RNAP. Cell-free translation is
performed as follows: 75% v/v HeLa
cell extract, 30 M of each of the 20
amino acids, 27 mM HEPES KOH, pH
7.5, 1.2 mM ATP, 0.12 mM GTP, 18
mM creatine phosphate, 0.3 mM
spermidine, 44–224 mM KOAc, 16
mM KCl, 1.2 mM Mg(OAc)2, 90 g/mL
calf liver tRNA, 60 g/mL creatine
kinase, and purified mRNA.
25% v/v Chinese hamster ovary cell
extract, 100 M of each of the 20
amino acids, 1.75 mM ATP, 0.30 mM
CTP, 0.30 mM GTP, 0.30 mM UTP, 20
nM DNA template, 1 U/L T7 RNAP,
30 mM HEPES KOH, pH 7.6, 150 mM
KOAc, 3.9 mM Mg(OAc)2, 20 mM
creatine phosphate, 100 g/mL
creatine kinase, 0.25 mM spermidine,
and 2.5 mM DTT.

Creatine
phosphate +
creatine kinase

[135]

Creatine
phosphate +
creatine kinase

[18]

Creatine
phosphate +
creatine kinase

[13]

Creatine
phosphate +
creatine kinase

[17]

1.1.4.5. Time
Overall, wheat germ and rabbit reticulocyte are the most time-consuming
preparations, at 4–5 days for wheat germ and up to 9 days for rabbit, if treatment of
animals is needed. All other platforms hover around the 1–2 day mark for preparation, with
highly variable growth times dependent on doubling time for the strain and final cell density
desired for harvest. E. coli requires the least time for preparation from the initiation of
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culture growth to the final freezing of extract due to its quick doubling time and relatively
simple extract preparation procedure.
1.1.5. Standard Optimizations
A variety of internal development of the CFPS platforms is constantly occurring in
order to improve protein yields and streamline extract preparation. Some major advances
have greatly improved a variety of the CFPS platforms, such as internal ribosome entry
sites (IRESs), species-independent translational leaders (SITS), and 5′UTR optimization.
These have improved the rates of translation in eukaryotic platforms, which can limit
protein yield. 5′UTRs are used to mimic cap structures and promote binding of the
ribosome to the mRNA template, but in some cases they have also been found to be
unhelpful or even detrimental to productivity. Additionally, 5′UTR choice may require some
testing and optimization before application [6,11,19,202]. IRESs are sequences utilized by
viruses to hijack cellular machinery for replication. They have been added to CFPS
templates in order to bypass translation initiation factors, but many are speciesdependent. However, IRESs have been used in rabbit reticulocyte, Chinese hamster
ovary, yeast, and Leishmania tarentolae [64,203–205]. SITS are unstructured translation
leaders that allow transcribed mRNA to interact directly with ribosomes across a variety
of CFPS platforms from many cell types, such that translation initiation factors are not
needed [11,190,193]. Codon optimization of the template DNA has also been used to
improve yields in eukaryotic platforms [73].
In addition to template optimization, many high adoption platforms have undergone
optimization of cell-free reaction reagent concentrations through systematic titrations of
the main reagents [197,206]. Additionally, protein yields can be augmented by the addition
of purified transcriptional and translational components or molecular crowding agents
[207,208].
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1.1.6. Conclusions
This review is aimed at helping new users of CFPS platforms determine which
platform best suits their needs. We sought to highlight similarities and differences among
the platforms, the applications that can be achieved by each, and the reasons one platform
may be more advantageous for a certain goal than another.
We recommend new users first investigate the high adoption platforms to find one
that suits them, as these platforms have been best optimized and there is plentiful
literature to support the user. High adoption platforms include E. coli, insect, yeast,
Chinese hamster ovary, rabbit reticulocyte, wheat germ, and HeLa. For these platforms,
we have covered a wide spectrum of applications that are enabled by each, to provide the
reader with an idea of the breadth of possibilities in CFPS, as well as to hopefully cover a
wide spectrum of user needs. These applications include education, post-translational
modifications, high-throughput expression, virus-like particles production, large-scale
synthesis, membrane proteins, difficult-to-synthesize proteins (antibodies, large proteins,
ice-structuring proteins, and metalloproteins), and miscellaneous applications (studies of
translational machinery, genetic code expansion, metabolic engineering, and genetic
circuits). In addition, we have covered the methods for growth, extract preparation, and
cell-free reaction setup, as well as batch reaction protein yield, such that the reader can
further determine if the platform suits their needs and obtain a better understanding of
what is required for successful implementation of each.
We also briefly covered the applications enabled by low adoption platforms including
Neurospora crassa, Streptomyces, Vibrio natriegens, Bacillus subtilis, tobacco,
Arabidopsis, Pseudomonas putida, Bacillus megaterium, Archaea, and Leishmania
tarentolae. While these platforms have some work supporting their use, they have
generally been used by only a few and are not as well optimized. However, these platforms
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may still provide some key advantages to the field if more work is done with them.
Additionally, the emerging platforms of Vibrio natriegens, Streptomyces, Bacillus subtilis,
Bacillus megaterium, and Pseudomonas putida are proposed to enable exciting new
applications of CFPS, including natural product synthesis from high GC templates.
1.2. Summary of Contributions
In summary, the aforementioned review of the CFPS field serves as a
comprehensive document that effectively lowers the barrier-to-entry for new users
looking to implement CFPS into their respective laboratories. Through the provided
descriptions of reaction setup, past, present and emerging cell lines with accompanying
applications, methodological differences between platforms, and general optimizations,
the review stands as an all-inclusive document to the CFPS field that has already been
widely viewed by numerous researchers spanning many fields. In addition to the review,
a thorough methodology for the process of going from E. coli cells to a completed cellfree protein synthesis reaction has been optimized and provided to the broad research
community at the following link: https:/www.jove.com/video/58882. The video-based
publication enables new users to quickly access a complex and nuanced protocol within
a ten-minute video with provided step-by-step protocols, a four-day timeline, and
platform optimization and storage figures. Together, these two documents help to
democratize the CFPS field to the broad scientific community and have already garnered
extensive viewership.
To further lower the barrier-to-entry into the CFPS field, Chapter 2 builds upon
the aforementioned methods by redesigning the upstream workflow for E.coli CFPS into
one that can be completed in under 24-hour’s time. Moreover, the new workflow allows a
400% increase in extract attained while significantly decreasing the researcher oversight
throughout the process. Through these optimizations and developments to E.coli-based
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CFPS, Chapter 3 utilizes the flexibility of CFPS to synthesize enzymes within a
nonribosomal peptide synthase that span over 100 kilodaltons.
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Chapter 2

2. REDESIGNED UPSTREAM PROCESSING ENABLES A 24-HOUR WORKFLOW
FROM E. COLI CELLS TO CELL-FREE PROTEIN SYNTHESIS
Modified from a version submitted to bioRxiv.
2.1 Introduction
To date, the E.coli platform has emerged as a workhorse in the field of CFPS due
to its robust capability for protein expression, diversity in protein production, eased of
culturing, and cost-effectiveness(Carlson, Gan, Hodgman, & Jewett, 2012). The broad
adoption of the E. coli-based crude extracts for CFPS is in part a function of consistent
effort by the scientific community to enhance robustness of the platform, streamline the
workflow of generating and utilizing cell extracts, and expand the utility and accessibility
for new users. From its inception in the 1950s when Nirenberg and Matthaei first used
CFPS to decipher the genetic code, there have been numerous advances in both energy
systems and laboratory workflows to make CFPS a viable protein expression platform
for applications ranging from discovery through manufacturing (Nirenberg & Matthaei,
1961). Energy systems have been consistently tuned to allow for high protein titers while
regenerating substrates to allow for longer lasting reactions with reduced costs (Jewett &
Swartz, 2004). Workflow optimizations include, but are not limited to: growth within
baffled flasks, the advancement of sonication-based lysis or bead beating, the utilization
of tabletop centrifuges to separate transcriptional and translational machinery from cell
lysate, and the ability to scale extract preparation to the 100 L-scale, (Dopp & Reuel,
2018; Kwon & Jewett, 2015; Levine, Gregorio, Jewett, Watts, & Oza, 2019; Shrestha,
Holland, & Bundy, 2012; Sun et al., 2013; Zawada et al., 2011). Most of these advances
improved the downstream processing, from cell lysis methods to CFPS reaction
conditions to support long-lived, high yielding reactions that are also capable of
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producing traditionally intractable proteins. The primary improvement to upstream
processing over the last 15 years has been the increasing use of baffled flasks for cell
growth instead of fermenters, otherwise, the process of growing and harvesting cells
appears to have remained unchanged (Kwon & Jewett, 2015; Liu, Zawada, & Swartz,
2005).
Efforts described herein seeks to redefine the upstream processing required to
generate E. coli-based crude lysates capable of supporting robust CFPS reactions. We
define upstream processing as the steps involved in cell growth and harvesting
workflow, starting from the originating cell through cell lysis for crude extract preparation.
The impetus for improving this workflow is two-fold: A) to reduce the number of technical
steps as well as the time and labor associated with upstream processing and B) to
improve reproducibility of CFPS from batch-to-batch, user-to-user, and across
institutions. The upstream workflow represents the most time-consuming aspect of cell
extract preparation, requiring 2-3 days to execute (Levine et al., 2019; Romantseva &
Strychalski, 2019). Steps include 1) streak plates from glycerol stocks (day 1); 2) grow
seed cultures from streak plates (day 2); 3) inoculate large volume growths with OD 600
monitoring for induction of T7 RNAP and harvest at precise phases of growth and
perform multiple bacterial pellet washing resuspensions prior to storage of cell pellets for
later lysis (day 3) (Kwon & Jewett, 2015; Liu et al., 2005; Shrestha et al., 2012; Sun et
al., 2013). Downstream processing steps of cell lysis and CFPS reactions can be done
immediately following harvest on day three, but often follow on a fourth day that may
occur much later in time.
Toward our goal, we have developed a cell-free autoinduction (CFAI) media
formulation (Table 5) for E. coli BL21Star™(DE3) that enables us to obviate the most
nuanced and burdensome steps of the existing upstream processing workflow. The
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outcome is the simplification of a ~3-day workflow down to a 24-hour workflow (Figure
1). Notably, CFAI supports cell growth to high cell densities without sacrificing cell
extract productivity. The capacity to generate robust cell extracts from high density
cultures results in >400% increase in total extract volume, further improving the value of
this approach. Our new approach is simple, reproducible, and decreases the time and
labor required, while also increasing the quantity of robust cell extract obtained.
Together, the advantages will further reduce the barriers to broad adoption of the CFPS
platform.

Figure 7. Timeline of CFPS workflow in under 24 hours utilizing the methods presented
in this work.
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2.2 Methods
2.2.1 Materials:
All materials used in this manuscript have been previously described (Levine et
al., 2019) with the exception of D-lactose (Alfa Aesar), glycerol (Sigma), and MILLEX-HV
0.22 μm Filter Unit (MILLIPORE, Carrigtwohil, Co. Cork, Ireland).
2.2.2 Cell Growth:
All growths derived from E. coli BL21Star™(DE3) cells (generously provided by
the Jewett Laboratory) are acquired from a glycerol stock and streaked onto an LB agar
plate less than two weeks old and stored at 4°C. Streak plates were used within two
weeks of inoculation.
2.2.2.1. 2x YTPG Media Growth
A solution of 750 mL 2x YTP was prepared by dissolving 5.0 g sodium chloride,
16.0 g of tryptone, 10.0 g of yeast extract, 7.0 g of potassium phosphate dibasic, and 3.0
g of potassium phosphate monobasic into Nanopure™ water. The solution was adjusted
to a pH of 7.2 using 5 M KOH. 250 mL glucose solution was created by combining 250
mL of Nanopure™ water with 18 g of D-glucose. The 2x YTP was transferred to a 2.5 L
TunairTM baffled flask and the glucose solution was transferred to an autoclavable glass
bottle. Both solutions were autoclaved for 30 minutes at121°C. A single colony of E. coli
BL21Star™(DE3) was inoculated into a seed culture of 50 mL of sterile LB and grown
overnight at 37°C and 200 rpm. The following day, a 2.5 L TunairTM Baffled flask
containing 1 L of 2x YTPG was inoculated from the seed culture to reach an OD600 of
0.1. The culture was incubated at 37°C while shaking at 200 rpm until OD600 reached
0.6. The 1 L media was then induced with a final concentration of 1 mM of Isopropyl β-D1-thiogalactopyranoside (IPTG). The culture was then harvested at an OD600 of 2.5.
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2.2.2.2. AI Media Growth
The autoinduction media was prepared by adopting the recipe developed by
Studier, F. W. (Studier, 2005). In brief, 5.0 g of sodium chloride, 20.0 g of tryptone, 5.0 g
of yeast extract, 7.0 g of potassium phosphate dibasic, and 3.0 g of potassium
phosphate monobasic were dissolved into 960 mL of Nanopure™ water. The pH was
then adjusted to 7.2 using 5.0 M KOH, and autoclaved in the Tunair™ baffled flask for 30
minutes at 121°C. A separate 40 mL of sugar solution was prepared by dissolving 6.0
mL of 100% glycerol, 2.0 g of D-lactose, and 0.5 g of D-glucose into 34.0 mL of
Nanopure™ water. This sugar solution was sterilized using syringe filter sterilization.
Following the same procedure for a seed culture, a single colony of E. coli
BL21Star™(DE3) was inoculated into 50 mL of LB in a 125-mL Erlenmeyer flask and
grown overnight under 37°C at 200 rpm. The next day, a 2.5 L Tunair™ Baffled Flask
containing 1 L of AI media combined with its sugar solution was inoculated by the seed
overnight culture to reach an OD600 of 0.1. The culture was harvested at an OD600 of 2.5.
2.2.2.3. CFAI Media Growth
CFAI media was prepared by dissolving 5.0 g of sodium chloride, 20.0 g of
tryptone, 5.0 g of yeast extract, 14.0 g of potassium phosphate dibasic, and 6.0 g of
potassium phosphate, monobasic into 960 mL of Nanopure™ water. Subsequently, the
pH was adjusted to 7.2 using 5.0 M KOH and autoclaved for 30 minutes at 121°C. A
separate sugar solution was prepared by dissolving 6.0 mL of glycerol, 4.0 g of Dlactose, and 0.5 g of D-glucose into 34.0 mL of Nanopure™ water. The sugar solution
was filter-sterilized. The two solutions were mixed to complete the CFAI recipe prior to
inoculation. When indicated, glycerol concentrations were titrated (Figure 11). The same
seed culture inoculation procedure as above was followed for a 2.5 OD 600 harvest. For
high density cultures with no human intervention, a loopful (Figure 9) of the previously
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streaked E. coli BL21Star™(DE3) was directly inoculated into 1 L of CFAI media
contained in a 2.5 L Tunair™ baffled flask and incubated at 30°C while shaking at 200
rpm. The culture was grown overnight (approximately 15 hours) to an approximate OD600
of 10. In some cases, specified amounts of supplemental glycerol were spiked into the
culture after overnight growth, an hour prior to harvest.
2.2.2.4. Super CFAI Media Growth
Super-CFAI media consisted of 5.0 g of sodium chloride, 32.0 g of tryptone, 20.0
g of yeast extract, 14.0 g of potassium phosphate dibasic, and 6.0 g of potassium
phosphate, monobasic into 960 mL of Nanopure™ water. After the pH was adjusted to
7.2 using 5.0 M KOH, the solution was transferred and autoclaved in a 2.5 L Tunair™
baffled flask and autoclaved for 30 minutes at 121°C. A separate sugar solution was
prepared by dissolving 6.0 mL of glycerol, 4.0 g of D-lactose, and 0.5 g of D-glucose into
34.0 mL of Nanopure™ water. The sugar solution was syringe filter-sterilized. These
solutions were combined and inoculated with a loopful of colonies and grown overnight
at 30°C shaking at 200 rpm.
2.2.3. Cell Harvest
The 1 L media was transferred into a cold 1 L centrifuge bottle (Beckman
Coulter, Indianapolis, IN), then centrifuged at 5000 x g and 10°C for 10 minutes (Avanti
Ⓡ J-E Centrifuge, Beckman Coulter, Indianapolis, IN). After disposing the supernatant,
the remaining pellet was transferred to a cold 50 mL Falcon tube using a sterile spatula
(SmartSpatulaⓇ, LevGo, Inc., Berkeley, CA) while kept on ice. Then, cells were washed
once with 40-50 mL of cold S30 buffer (14 mM Mg(OAc)2, 10 mM Tris(OAc), 60 mM
KOAc, 2 mM dithiothreitol) by resuspension via vortexing with rest periods on ice. In
some specified cases, three washes were performed. The resuspension was centrifuged

75

at 5000 x g and 10°C for 10 minutes. After disposing the supernatant, the pellet was
weighed, then flash frozen via liquid nitrogen and kept at -80°C until extract preparation.
When extracts were prepared during the same day as the harvest, each pellet was flash
frozen prior to lysis.
2.2.4 Extract Preparation
The frozen cell pellet was combined with 1 mL of S30 buffer per 1 gram of cell
pellet and thawed on ice. Once thawed, the cell pellet was resuspended via vortexing
with rest periods on ice until no visible clumps of cells were observed. Then, 1.4 mL of
the solution was transferred into 1.5mL Eppendorf tubes. A Q125 Sonicator (Qsonica,
Newtown, CT) with a 3.175 mm probe was used at a frequency of 20 kHz and 50%
amplitude with three forty-five seconds on/fifty-nine seconds off cycles to perform cell
lysis. Immediately after, 4.5 µL of 1 M DTT was added to the lysate and inverted several
times. The lysate was then centrifuged using a Microfuge 22R Tabletop Centrifuge
(Beckman Coulter, Indianapolis, IN) at 18,000 × g and 4 °C for 10 minutes. Following
centrifugation, the supernatant was pipetted into a new 1.5 mL Eppendorf tube, flash
frozen in liquid nitrogen, and kept in a -80°C freezer until use.
2.2.5 Cell-free Protein Synthesis
Cell-free protein synthesis was performed in 15 µL reactions in 1.5 mL Eppendorf
tubes in triplicate unless otherwise noted. The standard condition of the reaction
included 16 ng/µL of pJL1-sfGFP plasmid, 2.1 µL of Solution A (1.2 mM ATP, 0.850 mM
GTP, 0.850 mM UTP, 0.850 mM CTP, 31.50 µg/mL folinic acid, 170.60 µg/mL tRNA,
0.40 mM nicotinamide adenine dinucleotide (NAD), 0.27 mM coenzyme A (CoA), 4.00
mM oxalic acid, 1.00 mM putrescine, 1.50 mM spermidine, and 57.33 mM HEPES
buffer), 2.2 µL of Solution B (10 mM Mg(Glu)2, 10 mM NH4(Glu), 130 mM K(Glu), 2 mM
each of the 20 amino acids, and 0.03 M phosphoenolpyruvate (PEP)), 5.0 µL of cell
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extract, and a varying volume of molecular-grade water to fill the reaction volume to 15
µL (Levine et al., 2019). Supplemental reactions included the exogenous addition of 100
μg/mL T7 RNAP (generously provided by the Jewett Laboratory). The cell-free protein
synthesis reaction was carried out at 37°C for a minimum of four hours.
2.2.6 Quantification of Reporter Protein
Fluorescence intensity of superfolder GFP (sfGFP) was measured in triplicate
per reaction with excitation and emission wavelengths of 485 and 528 nm respectively
using a half area 96-well black polystyrene plate (Corning Incorporated, Corning, NY)
containing 48 µL of 0.05 M HEPES solution (pH 7.2) and 2 µL of the cell-free protein
synthesis reaction product. Fluorescence measurements were conducted using a
Cytation 5 imaging reader (BioTek, Winwooski, VT). The fluorescence was then
converted to concentration of sfGFP (µg/mL) based upon a standard curve as previously
described (Levine et al., 2019).
2.3. Results
In efforts to reduce the time and labor associated with obtaining cells for extract
preparations, we first assessed whether three wash cycles of the bacterial pellet were
necessary prior to lysis of the cells. We determined that performing one wash instead of
three is not detrimental to the resulting cell extracts’ capacity to express the reporter
protein sfGFP (Figure 10) (Kwon & Jewett, 2015; Shrestha et al., 2012). From this point
onward, each cell pellet underwent only one wash regardless of media type. Additionally,
we did not perform a runoff reaction as it is not necessary for the BL21Star™(DE3)
strain (Kwon & Jewett, 2015).
Next, an autoinduction strategy was employed to obviate the need to induce cells
with IPTG, the costly lactose analog. An autoinduction media recipe adopted from F.W.
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Studier (Studier, 2005) is similar to 2x YTPG in yeast extract, tryptone, and phosphate
quantities, but differs significantly in carbon sources, significantly reducing the amount of
glucose in favor of added lactose and glycerol (Table 5). Replacement of glucose with
lactose and glycerol as carbon sources was of concern given that glucose
supplementation in 2x YTP was first developed to limit the expression of alkaline and
hexose phosphatases that would normally result in a buildup of inorganic phosphates,
metabolites detrimental to the CFPS reaction as well as to activate central metabolism
for energy recycling within the CFPS reactions (Jewett, Calhoun, Voloshin, Wuu, &
Swartz, 2008; Kim & Choi, 2000). To our surprise, replacing 2x YTPG with autoinduction
media displayed no significant difference in the extract’s capacity to perform in vitro
transcription and translation when cells were harvested at an OD 600 of 2.5 (Figure 2).
Reducing the requirement to monitor OD600 for T7 RNAP induction and performing 1
wash instead of 3 washes provides minor but noteworthy improvements to the workflow.
However, growth in autoinduction media remains
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Figure 8. [sfGFP] versus various media recipes harvested at OD600 of 2.5 and 10.0. All
values are derived from three independent cell extract preparations from three independent
1 L media growths for each condition. Concentration values were calculated from the
average of cell-free protein synthesis reactions performed in triplicate for each cell extract
that underwent three independent measurements. All error bars represent one standard
deviation of the average of three independent reactions for each condition performed in
triplicate. Bolded ingredients represent modifications from the 2x YTPG media formulation.
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dependent on harvesting cells within a precise window of cell growth during the early to
mid-logarithmic phase in which cells are undergoing rapid doubling at which point
ribosomes and associated translational proteins are thought to be in high abundance
(Hong, Seok Hoon, Kwon, Yong-Chan, Martin, Soye, Paz, & Swonger, 2016; Kwon &
Jewett, 2015; Martin et al., 2018; Piir, Paier, Liiv, Tenson, & Maiväli, 2011). A downside
to this approach is that it tethers the researcher to monitoring cell densities for the
duration of the growth, increasing the labor and opportunity cost associated with
obtaining cells for CFPS. We sought to test the previous observations that established
the optimal OD600 for harvesting cells (Dopp & Reuel, 2018; Kwon & Jewett, 2015).
Toward this end, cells were grown to high densities, OD600 of 10, in both 2x YTPG and
autoinduction media. Our observations confirmed previous findings that extracts
generated from cells harvested at high cell densities nearing stationary phase of growth
in either 2x YTPG or autoinduction media show a depressed capacity for protein
production compared to extracts generated from cells harvested at an OD 600 of 2.5
(Figure 2).
We sought to identify whether the necessity to harvest cells at mid-log phase of
growth is a result of functional limitations other than translation machinery. We observed
that depressed CFPS yields from high cell density cultures correlate with more acidic
culture conditions at harvest (Table 1). To test the role of pH destabilization, we
increased the buffering capacity of the AI media by two-fold. Additionally, we
hypothesized that the extended growth times may exhaust the lactose carbon source
available in the AI media, resulting in depressed expression of T7 RNAP and/or altered
metabolism of the cells, becoming incompatible with the PANOxSP energy system in our
CFPS reactions. To address these concerns, we also increased the lactose
concentration by two-fold within the AI media (Table 5). Cells grown in the new media
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formulation were first cultured to an OD600 of 2.5 in order to establish whether the added
buffering capacity or lactose are detrimental to the resulting extract. Data displayed in
Figure 2 deemed that the extract resulting from the modified AI media performed
robustly, yielding >1 mg/mL of reporter protein. Cells were then grown to an OD 600 of 10
in the high lactose and high buffering capacity autoinduction media, washed once, and
processed for extract preparation. The extract resulting from cells grown to high
densities resulted in highly active cell extracts capable of producing >1 mg/mL of
reporter protein sfGFP (Figure 2). These findings demonstrated that our cell-free
autoinduction (CFAI) media formulation expands the limits of the traditional cell growth
workflow.
Table 4. Cell pellet mass and extract volume generated from corresponding media types
grown in triplicate. Values were averaged across triplicate growths.
2xYTPG

AI

CFAI

OD600

2.5

10

2.5

10

2.5

10

pH at Harvest

7.0

5.4

7.0

6.3

7.1

6.7

Cell Pellet (g)

4.21

14.22

4.79

17.4

4.13

13.9

Extract Volume (mL)

4.29

17.16

5.13

20.52

4.41

17.64

In order to maximize the potential of CFAI media, we evaluated the optimal
concentration of each component of our CFAI media. Toward this end, we tuned the
carbon source concentrations and timings of supplementing carbon source, as well as
yeast extract and tryptone quantities. Increased concentrations of glycerol were added to
the sugar recipe but provided no boost to the overall cell density or extract productivity
(Figure 11). To test the hypothesis that metabolic shifts as cells approach stationary
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phase play a role in limiting extract productivity, we also tested conditions where glycerol
was spiked into high density cultures 1 hour prior to harvest in efforts to reactivate
metabolism. These interventions also did not improve overall cell density or extract
productivity compared to CFAI media, confirming that the optimal conditions require
minimal human intervention in the workflow. We chose to maintain the current
concentration of glucose in order to provide the adequate threshold of energy in the
media to begin expressing the enzymes needed to uptake and begin metabolizing
lactose (Kopp et al., 2017; Studier, 2005). To identify whether the full potential of CFAI
was limited in other resources, yeast extract and tryptone were also augmented based
on the SuperBroth media recipe that is marketed for high density cultivation of E. coli
cells (Atlas, 2010). The resulting Super-CFAI media displayed similar OD600 values and
extract productivity levels as the CFAI media. These findings suggest that the added
cost of reagents for the Super CFAI media are not justified and that the CFAI media
formulation is optimal (Figure 12).
The capacity to obtain highly productive cell extracts from high density cell
cultures using CFAI media liberates the researcher from the time and labor associated
with existing workflows for cell growth. To expand on this capacity, we sought to reduce
or remove human intervention from all cell growth steps involved in the upstream
processing. Specifically, the traditional workflow requires the researcher to 1) generate
streak plates, 2) inoculate seed cultures from the colonies grown on the streak plates, 3)
inoculate larger volumes of media with the seed culture cells, and 4) monitor growth of
cells that will ultimately generate cell extract capable of in vitro transcription and
translation. Given the slow nature of cell propagation, this process consumes 2-3 days.
We tested a modified workflow in which colonies (Figure 9) of BL21Star™(DE3) from a
streak plate were inoculated directly into 1 L of CFAI media, incubated for 15 hours
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overnight, and harvested the subsequent morning. This experiment was conducted at
both 30°C and 37°C, and the resulting OD600 values were 8.0 and 10.0 respectively,
generating cell pellets of 15 g and 18 g respectively. Cells were washed once during
harvest and lysed via sonication for extract preparation. Extracts from both overnight
growths were robust, yielding >1 mg/mL of sfGFP, with the 30°C growth producing a
~10% higher titer than the 37°C growth. If streak plates and CFAI media are available,
this new workflow enables researchers to inoculate a liquid culture at 5 p.m., harvest at 8
a.m., generate extracts by 10 a.m., setup CFPS reactions by noon, and quantify by 3-4
p.m. In other words, this new workflow enables researchers to go from cells on a streak
plate to conducting and analyzing CFPS within 24 hours with under 6 hours of a
researcher’s active effort.
CFAI-based high density cell growth provides advantages beyond improved
workflows. The quantity of cells obtained from high density growths are ~4 times greater,
and the corresponding extract volumes obtained are also ~4 times larger (Table 1). As a
function of the simplicity, the CFAI-based workflow is also highly reproducible. To
evaluate this, we grew three independent cultures of each condition, performed three
independent extract preparations of each growth, tested each extract in triplicate CFPS
reactions, and subsequently quantified productivity of each reaction in triplicate. The
standard deviation resulting from these independent replicates is under 10% (Figure 2)
underscoring the reproducibility of the approach. Lastly, while the cost of 2x YTPG and
CFAI media are similar, increased extract volumes, combined with reduced researcher
time, makes this new approach significantly more cost-effective.
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2.4. Tables and Graphs

Table 5. Ingredient recipes for various media and sugar solutions used to make 1 L of
media in this work. (* sugar solution that may undergo autoclaving for 30 minutes,
121°C).
Autoclave for 30 minutes, 121°C:
2x YTPG
Media
Sodium Chloride
5.0 g
Tryptone
16.0 g
Yeast Extract
10.0 g
Potassium
phosphate,
7.0 g
dibasic
Potassium
phosphate,
3.0 g
monobasic
Nanopure™ Water
Up to 750 mL

AI
Media
5.0 g
20. g
5.0 g

CFAI
Media
5.0 g
20. g
5.0 g

Super-CFAI
Media
5.0 g
32 g
20.0 g

7 .0 g

14. g

14 g

3.0 g

6.0 g

6.0 g

Up to 960 mL

Up to 960 mL

Up to 960 mL

AI
Media
0.50 g
2.0 g
6.0 mL
Up to 40 mL

CFAI
Media
0.50 g
4.0 g
6.0 mL
Up to 40 mL

Super-CFAI
Media
0.50 g
4.0 g
6.0 mL
Up to 40 mL

Filter Sterilize:

D-Glucose
D-Lactose
Glycerol
Nanopure™ Water

2x YTPG
Media*
18.0 g
0g
0 mL
Up to 250 mL
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Figure 9. Pictures of a BL21*(DE3) LB streak plate before (A) and after (B) removing a
loopful of colonies for direct inoculation into 1 L of media.
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Figure 10. Comparison of one wash versus three washes of cell pellets during
harvesting of growths in 2x YTPG media for preparation of high yielding extracts. A
single pellet was split in half and underwent 3 washes versus 1 wash and then
underwent extract preparation. The resulting extracts underwent CFPS reactions in
triplicate for sfGFP, and the resulting fluorescence was measured in triplicate. All error
bars represent one standard deviation of the average of three independent reactions for
each condition.
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Figure 11. Glycerol supplementations to CFAI media prior (A) and post overnight growth
(B) resulted in decreased [sfGFP]. CFAI media formula underwent a 2x, 4x, and 6x
titration of the 1x glycerol formula in panel A (6mL of 100% glycerol). CFAI overnight
growths represented in panel B were grown at 30°C and at 37°C with one from each
respective temperature undergoing supplementation with 6 mL of 100% glycerol one
hour prior to harvest. Values represent averages across three independent reactions
measured in triplicate. All error bars represent one standard deviation of the average of
three independent reactions for each condition.
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Figure 12. Tryptone, yeast, and lactose supplementations to the CFAI media formula
displayed no added boost to [sfGFP]. Recipes for various media types are located in
Supplementary Table 1. Values represent averages across three independent reactions
measured in triplicate. All error bars represent one standard deviation of the average of
three independent reactions for each condition.
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CFAI

2.5
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2

1.5

1
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Figure 13. Growth rates of various media conditions from OD 600 of 0.1 to 2.5 resulted in
a significantly faster growth rate in autoinduction media (CFAI in orange; AI in grey)
compared to 2x YTPG media (blue). Values are averages across growths performed in
triplicate for each media type. All error bars represent one standard deviation of three
independent growths for each condition.
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4

Figure 14. Evaluation of T7 RNAP limitations in 2x YTPG and CFAI media. Extracts from
1 L growths of each media type were tested by cell-free protein synthesis reactions in
triplicate and production of sfGFP was measured in triplicate for each reaction. [sfGFP]
is not improved with exogenous addition of T7 RNAP across media types. All error bars
represent one standard deviation of the average of three independent reactions for each
condition.
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Chapter 3

3. A METABOLIC ENGINEERING APPLICATION OF CELL-FREE PROTEIN
SYNTHESIS
In addition to the efforts to democratize and develop CFPS, one direct application
of CFPS that was explored during the first year of my master’s experience was through
cell-free metabolic engineering (CFME) of an enzymatic pathway. CFME employs the
robust power of the CFPS platform to express enzymes that can be mixed to
recapitulate a naturally occurring metabolic pathway within a test-tube (Goering et al.,
2017). Additionally, CFME can be characterized as a strategy to explore new metabolic
pathways via the production of novel, non-naturally occurring peptides, or to validate
existing or new metabolic interactions between enzymes (Dudley, Anderson, & Jewett,
2016). I explored the application of CFME by touching on each of these applications
through the examination of a hybrid nonribosomal peptide synthase-polyketide synthase
(NRPS-PKS) pathway.
NRPS-PKS pathways are of high importance in biotechnology by way of the
capability to synthesize novel peptides that include toxins, siderophores, pigments, and
therapeutics, among others (Hahn & Stachelhaus, 2006). Functionally, NRPS-PKS
pathways consist of a complex of enzymes that sequentially bind, modify, and transfer
one amino acid at a time to the next enzyme within the complex as the peptide chain
grows in an assembly line-like fashion (Weissman, 2015). Each enzyme within an
NRPS-PKS pathway has strict specificity to transfer the growing peptide to the next
enzyme in the complex through short amino acid domains between the N and C termini
of cognate enzymes. These domains, referred to as communication-mediating (COM)
domains, also represent a novel area of study due to the specific nature and ability to
bind and release large enzyme complexes (Hahn & Stachelhaus, 2006). Past studies
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have demonstrated the interchangeability of numerous pairs of COM domains by
swapping them between normally noncognate enzyme partners to generate novel
peptide products (Hahn & Stachelhaus, 2004). In total, these pathways range greatly in
size depending on the number of enzymes and can total to upwards of 500 kilodaltons.
The NRPS-PKS pathway of interest for CFME was the epoxomicin synthase, a
natural metabolic pathway found within Goodfellowiella coeruleoviolacea, an
actinomycetes bacterium, which produces the novel polypeptide, epoxomicin (Liu, Zhu,
& Zhang, 2015). This novel polypeptide is of high therapeutic importance due to its
specificity for the 20S proteasome, a target for my many cancer therapies (Sin et al.,
1999). Moreover, the multiple myeloma therapeutic, Carfilzomib, was created as a
derivative of epoxomicin with only a few amino acid changes and the addition of a
morpholino-capped lead molecule (Adams, 2004). Carfilzomib allows for an increased
specificity and solubility for the targeting and shutdown of the 20S proteasome within
cancer cells in the human body (Kuhn et al., 2007). However, the current biosynthetic
creation of Carfilzomib accounts for an approximate $10,000 per month charge for each
patient prescribed the medication (Perel, Bliss, & Thomas, 2016). To address the high
cost as well as the potential to screen for even more efficient derivatives of epoxomicin,
the emergence of a CFME-based approach appears promising.
In accordance with this strategy, the Watts Laboratory at Cal Poly, SLO has
acquired and deconstructed the large, 15,294 base pair, epoxomicin synthase gene
cluster into six expression cassettes. Each cassette consists of a “dissected” portion of
the epoxomicin synthase located between a T7 promoter and T7 terminator with affinity
tags at each terminus. Additionally, within each cassette are sequences for cognate
COM domain pairs that are attached onto each adjacent 3’ and 5’ end that will facilitate
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interactions between the now “dissected” epoxomicin gene cluster. These expression
cassettes were then stitched into the pJL1 backbone, a popular vector for CFPS.
Upon optimizing the CFPS platform for robust yields with a reporter protein, I
was then able to successfully pilot the first two expression cassettes in CFPS,
demonstrating the capability of the CFPS platform to synthesize proteins exceeding 120
kilodaltons (Figure #1). However, truncation of the protein constructs was an ongoing
issue. Attempts to address truncation with no significant improvements within the CFPS
reaction involved a DMSO addition, protease inhibitor cocktail addition, tRNA and amino
acid titration, DNA titration, extract volume titration, and replacement of BL21*DE3
extract with BL21*-Rosetta2 extract (Rosetta2 plasmid kindly provided by the Black
Laboratory), BL21*-ELP (elongation factor proline) extract, and BL21-Rosetta-ELP
extract. A significant success to the truncation issue appeared to be the designation of a
new ribosomal binding site to the expression plasmid which reduced many of the
truncated protein bands (data not shown). Future experiments will determine the
functionality of the COM domains between the pairs of enzyme constructs through a
dipeptide assay performed by the Watts Laboratory.

93

Figure #9. Western Blot analysis of successful full-length expression of epoxomicin
synthase modules 1 and 2 in CFPS vs in vivo expression. Each CFPS reaction is
comprised of 5μl cell extract in a 15μl total volume and was performed for 4 hours at
37C. In vivo expression was performed following traditional methods overnight at 37C.
N-term Strep Tags were detected using anti-strep tag II antibody for Module 1, Module 2,
and sfGFP. Anti-strep tag II antibody was used to detect Module 1 and Module 2 using
the same protocol but for a C-term tag. Protein samples were run on a 12% SDS-PAGE
gel. Asterisk denotes full-length protein of interest.
On a separate but related front, the first three pairs of COM domains that had
been positioned onto the deconstructed epoxomicin modules were placed onto two
noncognate NRPS enzymes, GrsA and TycB1 of the Gramicidin S and Tyrocidine
complexes for future binding kinetics studies. These enzymes have undergone many
COM domain swapping experiments that have determined the necessary residues within
COM domains that are needed for an interaction to occur; however, there has not been
a study on the binding affinity among cognate COM domain pairs (Hahn & Stachelhaus,
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2004). Binding kinetics will be assessed via a fluorescence polarization assay with the
addition of a fluorophore, Alexa Fluor-488. The fluorophore will be bound to cysteine
residues present within one enzyme and will be titrated in solution against the other. The
fluorescence polarization assay relies on the rotational correlation time of the enzymes
tumbling in solution and should decrease as pairwise binding between enzymes occurs
(Oza, Sowers, & Perona, 2012). Through utilization of this assay, future studies in the
Watts and Oza Laboratories hope to assign Kd values to these COM domain pairs. In all,
these metabolic engineering applications display the flexibility and power of CFPS to
express large, modular enzymes and to evaluate protein-protein interactions.
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Chapter 4
4. DISCUSSION, CONCLUSION, AND FUTURE DIRECTIONS
4.1. Discussion
The results presented here demonstrate the development of a new upstream
workflow for performing E. coli crude lysate-based cell-free protein synthesis. The new
approach provides four key advantages over past workflows by: 1) decreasing the
overall time by from a four day process to just under 24 hours, 2) decreasing the labor
and oversight required from the researcher, 3) increasing the extract obtained by
~400%, 4) removing the need to introduce exogenous T7 RNAP to CFPS reactions.
Directly inoculating a 1 L volume of media with a loopful of colonies and obviating the
seed culture reduces the workflow by an entire day’s time. Although standard
microbiology growth procedures often rely on a single colony to limit genetic diversity,
the streak plate is generated from an isogenic glycerol stock. Additionally, many
biotechnology endeavors utilize the inoculation of multiple colonies into a liquid cultures
to support their biotechnology applications (Pirman et al., 2015; Zhu, Gafken, Mehl, &
Cooley, 2019). Moreover, the cell extracts produced from our growths have been shown
to have reproducible robustness from batch-to-batch, reducing immediate concerns
associated with the genetic diversity arising from multiple colonies. For these reasons,
we maintain that inoculating with multiple colonies from a fresh plate (less than two
weeks old and stored at 4°C) of BL21Star™(DE3) that is generated from an isogenic
glycerol stock is suitable for CFPS applications. Next, the rationale for using a seed
culture is to expedite cell growth in large volumes; the seed culture allowed researchers
to begin growth of a 1 L culture at an OD600 of 0.1 - 0.3 in order to reach OD600 of 2.5
in a timely manner. The capacity to obtain robust extracts from high density cell cultures
that have autoinduced T7 RNAP expression obviates the need to monitor cell densities
for induction of T7 RNAP between OD600 of 0.6 - 0.8 or for harvest at mid-log phase
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and therefore, eliminates the need for seed cultures (Kwon & Jewett, 2015; Levine et al.,
2019; Liu et al., 2005; Shrestha et al., 2012; Sun et al., 2013).
Following cell harvest, the time needed to wash the bacterial pellet is reduced to
a third by using one washing step instead of three which displayed no drop in overall
productivity of the cell extract (Figure 10). Given that cell pellets are increasingly difficult
to resuspend after each wash, the practical time and labor savings are likely greater than
3-fold. Moreover, our recipe still allows for a typical OD600 2.5 harvest if large amounts
of extract are not necessary, and it achieves this cell density at a faster growth rate than
standard 2x YTPG media (Figure 13). As a result, a researcher can inoculate a loopful of
colonies in the morning and harvest at OD600 2.5 seven hours later prior to going home
for the day. In addition to the aforementioned advantages, researchers looking to
maintain their current workflows may find CFAI superior to 2x YTPG for improved growth
rates as another source of time reduction. Lastly, our data showed that CFAI-based
extracts are not limited by T7 RNAP and do not benefit from supplementation of purified
enzyme which suggests that there is sufficient induction of the lac operon throughout the
growth period (Figure 14).
In all, these efforts have resulted in the development of a new upstream workflow
for the preparation of E. coli extract. The CFAI media-based workflow provides
researchers with an economical and reproducible strategy to generate large volumes of
robust cell extracts capable of producing over 1 mg/mL of reporter protein. Notably, a
researcher stocked with CFAI media and a streak plate can go from cells to CFPS within
24 hours in a ‘set it and forget it’ manner. We hope this innovation will transform the
workflow for existing CFPS researchers and reduce the barrier to entry for new users.
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4.2. Conclusion
Through the provisions within this document, the future implementation of CFPS
into broader institutional and industrial audiences was clearly addressed. To limit the
barrier-to-entry of CFPS to these audiences, the comprehensive review, accessible
E.coli-based video protocol, and redesigned workflow materials all lead to an overall
ease of accessibility to CFPS for the broad research community. Each article has
already gained a substantial following by the research community, amassing over 10
citations in less than one year’s time. Moving forward, I anticipate that these articles will
not only continue to garner extensive viewership, but also lead to a reduced barrier-toentry for CFPS implementation among all types of institutions.
4.3. Future Directions
Aside from the improvements to democratizing CFPS and limiting its barrier-toentry via the articles presented herein, it is important to identify future directions of such
a continuously evolving and growing platform. With numerous possibilities for future
directions of the platform, I would like to focus on the areas of education, therapeutic and
vaccine production, biosensors, DNA compatibility within CFPS, and machine learning
applications.
4.3.1. Education
Education-based CFPS was first piloted at Stanford University in 2013 as a field
trip consisting of a brief laboratory lecture and laboratory for high school students. As a
part of the laboratory segment, students were able to perform a 60-minute CFPS
reaction and compare translation yields to a colored paper gradient (Albayrak, Jones, &
Swartz, 2013). In recent years, the creation of the BioBits Bright, Explorer, and Health
kits, have provided both middle and high school students with the opportunity to
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synthesize fluorescent proteins, hydrogels, identify fruit DNA, and explore CRISPR-Cas9
gene editing for an affordable cost to institutions (Huang et al., 2018; Stark et al., 2019,
2018). The creation of these kits has been made possible through the advent of stable
lyophilized extracts paired with the rapid reaction speed of CFPS allowing for an
effective distribution and implementation to classrooms. Moving forward on the topic of
education, the Oza Laboratory at Cal Poly has begun to pilot an undergraduate
laboratory-based CFPS kit, with the niche of exploring faster maturing fluorescent
proteins and CFPS additives to generate quicker reaction rates. In addition, the
incorporation of fluorescent aptamers by the Oza Laboratory could result in the real-time
visualization of both transcription and translation within a three-hour laboratory period.
Aptamer-based education has already emerged from developments within the Engelhart
Laboratory at the University of Minnesota where the DNA encoding the broccoli aptamer
is amplified, subsequently transcribed, and visualized with the binding of a fluoret within
an undergraduate laboratory period (Heili et al., 2018). The possibility of integrating
aptamer transcription within a CFPS-based assay could provide a dual fluorescence
experiment for undergraduate students to visualize both transcription and translation
within a single laboratory period.
4.3.2. Therapeutics and Vaccines
A very current and ever-growing direction of CFPS is the synthesis of clinically
deliverable therapeutics and vaccines. Successes in the synthesis of therapeutics and
vaccines through CFPS has already been established through a number of studies
including the synthesis of personalized lymphoma vaccines, malaria vaccine candidates,
an acute lymphoblastic leukemia therapeutic, and a tissue plasminogen activator to treat
ischemic stroke, among others (Kanter et al., 2007; Tsuboi, Takeo, Arumugam, Otsuki,
& Torii, 2010; Wilding et al., 2019; Yang et al., 2019). At an industrial level, companies
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like Sutro Biopharma and Sutrovax have emerged in recent years and have utilized
CFPS for the development of numerous therapeutics and vaccines ranging from
treatments to multiple myeloma and ovarian cancer (Sutro Biopharma) to vaccines for
human papilloma virus, herpes zoster, and measles (Sutrovax). The speed, flexibility,
and open nature of the CFPS platform will allow it to remain a novel method for vaccine
and therapeutic production moving forward.
4.3.3. Biosensors
A recent popularity for cell-free biosensors has emerged over the past few years
for detection of a handful of complex substances and hazardous chemicals. This
popularity has been made possible through the advancements of storage and portability
of cell-free extracts through lyophilization and paper-based utilization. By simply
hydrating a CFPS reaction on a paper-based device, the detection of numerous
compounds becomes possible outside of the laboratory. Already, cell-free biosensors for
water samples containing fluoride, mercury, and atrazine have been established (Gupta,
Sarkar, Katranidis, & Bhattacharya, 2019; Silverman, Akova, Alam, Jewett, & Lucks,
2019; Thavarajah et al., 2019). Additionally, biosensors for more complex compounds
like benzoic acid, date-rape drugs, and zika virus have also been created (Gräwe et al.,
2019; Pardee et al., 2016; Voyvodic et al., 2019). With this growing popularity, it is
possible that future cell-free biosensors could emerge to test an even wider variety of
samples, and even integrate for multiple detections at once. As an example, the
combination of multiple water contaminants onto one paper-based device, each capable
of emitting a different fluorescent signal could allow for an all-in-one sensor for water
contaminants. A similar strategy could be applied to multiple drug compounds within a
single reaction, again generating a different fluorescent emission for each drug within a
subject’s system.
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4.3.4. DNA Limitations
Addressing DNA limitations within CFPS is a future direction that was not
explored through my efforts but was highlighted as another recommendation through the
NIST CELL-FREE report. The report called for a standardization of more universal DNA
preparation techniques for CFPS. To date, standard midi and maxi prep kits are used to
generate plasmid DNA for CFPS; however, they often result in inconsistent protein titers
post-CFPS reaction (Romantseva & Strychalski, 2019). Often times, these DNA
preparations will undergo subsequent purification steps including excess ethanol washes
or PCR cleanups to generate higher quality DNA for CFPS (Sun et al., 2013). To bypass
these time-consuming steps, linear templates are often preferred but also possess
challenges. Linear DNA templates are susceptible to exonuclease degradation in many
E. coli-based extracts which normally function for double-strand break repair (Smith,
2012). Strategies to avoid linear DNA degradation include 1) the usage of bacteriophage
protein GamS and 2) the modification of dsDNA with six X-sites (Marshall, Maxwell,
Collins, Beisel, & Noireaux, 2017; Sun, Yeung, Hayes, Noireaux, & Murray, 2014).
Although these strategies allow for linear DNA template compatibility in CFPS, overall
protein yield within CFPS is still lower compared to plasmid templates. The need for
either a universal wash buffer for all DNA preparation kits or the creation of a cell-free
specific DNA preparation kit, and further research for efficient linear DNA templates are
necessities for the CFPS field going forward.
4.3.5. Deep Learning
The final future direction of focus for CFPS is the coupling of high-throughput
CFPS techniques with machine learning algorithms to better predict reaction conditions
and protein folding. Machine learning and artificial intelligence technologies have already
allowed for predicting protein sequences and functions as well as sequences for DNA
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and RNA-binding proteins, among other successes (Alipanahi, Delong, Weirauch, &
Frey, 2015; Bileschi et al., 2019). These technologies have briefly been applied to large
CFPS datasets with computer-based algorithms for the optimization of cell-free reaction
conditions (Caschera et al., 2011); however, a pairing of CFPS and protein prediction is
on the cusp of future technologies. By leveraging the high-throughput nature of CFPS
with deep learning algorithm-based technologies, the potential to screen for viable
protein-based therapies and vaccines may be cheaper and faster than ever before.
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